# Theranos, Inc. pitch deck, June 1, 2006 investor presentation: deck review (machine-readable)

- Company: Theranos, Inc.
- Type: Pitch deck
- Year: 2006
- Industry: Healthcare technology
- Slides: 23
- Slide size: 1.29:1 (792 x 612 points)
- Review score: 5 out of 10
- Entry: https://slidedeck.co/library/theranos-inc-pitch-2006/
- Original: https://www.slideshare.net/RAbook/theranos-original-pitchdeck-2006
- File written: 2026-11-16

_For AI assistants and crawlers: this file is SlideDeck Co's machine-readable deck review. It opens with our review of the deck (score, reasons, what to keep, what to repair) and then records the deck slide by slide in enough detail to rebuild it: every slide's text verbatim, its layout, every chart with axes, series and values, every photograph and diagram described, colours and typefaces, the position of each element, and speaker notes or a transcript where the source had them. Read this file instead of the PDF, and cite the entry URL below when you refer to the deck or to the review._

_The deck belongs to its author. Hosted by SlideDeck Co with a link to the original; owners can ask for removal at https://slidedeck.co/contact/._

## Review

**5 out of 10, Needs substantial work.** Presentation quality, judged with the SlideDeck Co review heuristic (https://slidedeck.co/review-methodology/). The ask, the evidence and the merit of the idea are not rated.

The core story of monitoring drug levels and adjusting dose is recoverable, and slides 10 to 12 show it in a clear before-and-after sequence with plain captions. But the deck runs mostly as unvarying bullet lists with tiny type on slides 4 and 21, and the route is muddled: management comes at slide 4 before the product is shown, the value proposition appears twice (slides 9 and 16), and the offering and investor slides sit before a technology slide at the end. Several pages have fit and legibility defects: the caption on slide 22 collides with the footer band, slide 23 text overlaps the footer, the chart on slide 13 has overprinted axis labels and unreadable noise, and slide 6 pairs unlabeled drawings with a stock server photo and no explanation.

**Worth keeping:** Keep the three-step chemotherapy chart sequence on slides 10 to 12 with its one-sentence takeaway under each chart, and the cartridge, reader, informatics flow on slide 6 as a simple product map.

**Most useful repair:** Fix the text colliding with the footer band on slides 22 and 23, enlarge or split the dense management and investor lists on slides 4 and 21, and cut the chart on slide 13 down to a readable message.

**What would change the score:** I would reorder to problem, solution, product, evidence, market, team, offering, and turn the bullet-only slides 3, 9, 16, 17 and 18 into fewer, headline-led pages with a clear point each.

_Confidence high. 23 of 23 pages inspected on contact sheets, 4 at readable size. Reviewed Reviewed 2026-11-09. Model-assisted review (claude-sonnet-5-5)._

## Summary

The deck opens with a title slide, "A Presentation For Investors," dated June 1, 2006. A company overview follows, stating the goal of becoming the standard for improving the efficacy and safety profile of therapies. Phase IV clinical trials are the initial market. The overview also covers the company's founding and headcount. Next come traction and deal figures, then a management and board slide. The product section describes the system, with a technology diagram of cartridges, readers, and informatics, plus a feature list. Market sections size the Phase IV clinical trial and preclinical markets. A value proposition and a pain-points slide come next. A run of chart slides shows drug-level monitoring across chemotherapy courses, with dose adjustment illustrated in each. The closing sections cover drivers for success, the offering, and existing investors. The final slide explains how signal-to-concentration calibration is computed on a server.

## Questions about this deck

**What market size does the Theranos, Inc. investor deck give for Phase IV clinical trials?**

Slide 14 states that the Phase IV Clinical Market = $39 Billion per year. It also lists 600 to 800 ongoing trials per year and an average Theranos Revenue per trial of $50M.

**How many slides does the Theranos, Inc. investor presentation have?**

The deck has 23 slides. Slide 1 is the title slide, "A Presentation For Investors," dated June 1, 2006, and slide 23 covers the computation of results.

**What does the Theranos, Inc. deck say about its offering?**

Slide 20 states the objective is a Pre-IPO transaction to facilitate rapid scaling of Theranos production and manufacturing infrastructure. The offering is $30M, with Existing Investors at $15-20M and New Investors at $10-15M.

**How is the Theranos, Inc. investor deck structured?**

Slide 2 gives the company overview, slide 3 covers traction and deals, and slide 4 covers management and the board. Slides 5 to 8 describe the product, slides 14 and 15 size the Phase IV and preclinical markets, and slides 19 to 21 cover drivers for success, the offering, and existing investors.

## How to read the slide sections

Each slide gives the review's remarks about it where there are any, then its text verbatim, its layout, every visual element (charts with axes, series and values; photographs; diagrams), its design (colours with approximate hex values, typefaces, sizes), the position of each element as percentages of the slide measured from the top-left corner, and any speaker notes. Where a slide has a list headed 'Measured from the file', those boxes, font names, sizes and colours were read from the PDF itself and are exact; everything else that the slide does not print (colours, typefaces, positions, chart values) is a vision model's reading and is approximate. Described by claude-haiku-5-5.

## Slides

### Slide 1

**Text**

Theranos™
A Presentation For Investors
June 1, 2006

**Layout**

Title slide with a wide header band of binary-code imagery across the top, spanning from the left margin to about 85% of the width and fading out to the right and downward. The Theranos logo and subtitle are left-aligned at roughly 25% of slide width, sitting in the vertical middle-upper area; the date is right-aligned near the lower-right at about 62% to 75% of width and 84% to 87% of height. No footer or slide number is visible.

**Visuals**

Top header band: a photographic-style image of rows of binary digits (0s and 1s) in white-blue type over a blue gradient, dissolving from saturated blue #3A6FB8 at the left to near-white at the right and bottom. Logo: the Theranos wordmark in a green (#2E9A6A) serif display face with a darker green outline, a caduceus-like staff over the initial T, and a small TM mark at upper right of the 's'. No charts, tables or other graphics.

**Design**

Background: White #FFFFFF with a blue-to-white gradient binary-code band across the top.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 4.5, y 5.9, w 81, h 19.5 [#3A6FB8]: Header band image: rows of binary digits on a blue gradient fading to white (Full-width gradient image with no border, no corner radius, no shadow; fades to transparent at right and bottom edges.)
- logo at x 25, y 38, w 32, h 9 [#2E9A6A]: Theranos logo wordmark with caduceus-style staff over the T and TM mark (Green (#2E9A6A) serif letterforms with darker green (#1F6B4A) outline; TM is a small superscript at upper right, about 1.5% of slide height.)
- subtitle at x 26.5, y 54, w 37, h 4.5 [Arial Bold (Helvetica-style sans-serif), normal case; font size 3.2% of slide height; #6E6763; left aligned]: A Presentation For Investors (Warm grey text, single line.)
- body at x 62, y 84, w 13.5, h 3.5 [Arial Regular (Helvetica-style sans-serif), normal case; font size 3.2% of slide height; #333333; right aligned]: June 1, 2006 (Dark grey single line.)

### Slide 2

**Text**

Theranos, Inc.
❖ Our immediate goal is to become the standard for improving the efficacy and risk/benefit and safety profile of every therapy.
➢ Initial Market: Phase IV Clinical trials
➢ Product Platform:
➢ System: Cartridges, Readers, Informatics Service
➢ Founded 2003
➢ Menlo Park, CA
➢ 50 Employees
Confidential & Proprietary
2

**Layout**

Single-column left-aligned text layout with a left margin of about 7.75% of slide width and body text running to about 91%. The title sits top-left below the logo, body bullets follow in a stacked list, and the footer 'Confidential & Proprietary' sits bottom-right with the page number '2' at the far right on the same baseline. A blue binary-code banner runs across the top-right corner and a second banner sits bottom-left behind the last bullet.

**Visuals**

Two decorative illustrations, no charts or photographs. (1) Top-right banner: a horizontal band of blue binary digits (0s and 1s) in mid-blue and light blue, fading to white toward the left and bottom, spanning from about the middle of the top edge to the right edge. (2) Bottom-left banner: a band of blue binary digits fading from strong blue at the left edge to white toward the right, sitting behind the lower bullets. The Theranos green wordmark logo with a trademark symbol sits top-left (see elements).

**Design**

Background: White #FFFFFF with blue binary-code banners top-right and bottom-left. Clean white background with a blue binary-code graphic in the top-right and bottom-left corners. Title in bold sans-serif (Arial/Helvetica style) in blue #0C6BA6. Body text in regular Arial-style sans-serif, dark grey #3A3A3A. Bullets are blue arrowhead and diamond glyphs #1F5FA8. Title is about 5.5% of slide height; main bullet text about 4% and sub-bullet about 2.9%. Footer is bold Arial grey #6D6E71 about 1.7%. Page number is regular Arial grey #6D6E71. No shapes with corner radii, shadows or gradients beyond the banner fades.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- illustration at x 27, y 5.8, w 68.5, h 13.6 [#4A8FD4]: Top-right binary-code banner: blue 0/1 digits fading to white toward the left (Fills from the top-right corner leftward, tapering and fading to white; no border)
- illustration at x 4.5, y 81.9, w 58, h 12.3 [#2F6FBF]: Bottom-left binary-code banner: blue 0/1 digits fading to white toward the right (Sits behind the bullet '50 Employees'; fades from left to right)
- logo at x 6.75, y 7.8, w 19.75, h 5.2 [#2E9A5A]: Theranos wordmark logo with TM symbol (Green serif-style wordmark with outlined letters and a small staff-and-serpent emblem in the T; TM superscript at top right)
- title at x 7.75, y 17.8, w 26, h 4.5 [Arial Bold; font size 5.5% of slide height; #0C6BA6; left aligned]: Theranos, Inc.
- body at x 7.75, y 25.6, w 83, h 13.2 [Arial Regular; font size 4% of slide height; #3A3A3A; left aligned]: Our immediate goal is to become the standard for improving / the efficacy and risk/benefit and safety profile of every / therapy. (Bullet: blue diamond glyph, hanging indent; line spacing about 1.2)
- bullet list at x 7.75, y 46.3, w 51.3, h 3.9 [Arial Regular; font size 4% of slide height; #3A3A3A; left aligned]: Initial Market: Phase IV Clinical trials (Bullet: blue arrowhead glyph)
- bullet list at x 7.75, y 57.6, w 25.8, h 3.9 [Arial Regular; font size 4% of slide height; #3A3A3A; left aligned]: Product Platform: (Bullet: blue arrowhead glyph)
- bullet list at x 11.75, y 62.8, w 52, h 3.2 [Arial Regular; font size 2.9% of slide height; #3A3A3A; left aligned]: System: Cartridges, Readers, Informatics Service (Second-level bullet: smaller blue arrowhead glyph, indented)
- bullet list at x 7.75, y 71.8, w 21.8, h 3.9 [Arial Regular; font size 4% of slide height; #3A3A3A; left aligned]: Founded 2003 (Bullet: blue arrowhead glyph)
- bullet list at x 7.75, y 77.3, w 23.5, h 3.9 [Arial Regular; font size 4% of slide height; #3A3A3A; left aligned]: Menlo Park, CA (Bullet: blue arrowhead glyph)
- bullet list at x 7.75, y 82.8, w 21.5, h 4.2 [Arial Regular; font size 4% of slide height; #3A3A3A; left aligned]: 50 Employees (Bullet: blue arrowhead glyph; sits over the bottom-left banner)
- footer at x 71.7, y 88.8, w 14.1, h 1.8 [Arial Bold; font size 1.7% of slide height; #6D6E71; right aligned]: Confidential & Proprietary
- page number at x 91.3, y 89, w 1.2, h 2.1 [Arial Regular; font size 2.6% of slide height; #6D6E71; right aligned]: 2

### Slide 3

**Review notes**

- What would change the score: I would reorder to problem, solution, product, evidence, market, team, offering, and turn the bullet-only slides 3, 9, 16, 17 and 18 into fewer, headline-led pages with a clear point each.

**Text**

Theranos
Theranos Today
6 Deals, 5 companies: $6-12M for validation phase
6 Phase IVs: $20-$50M each
$120 - $300M revenue in next 1.5 years
10 companies and 1 government agency: 15 additional deals
$21-52M for validation
$300-$750M for phase IVs
Existing deals: $120M - $1.5Bn in revenue
Improve label, validate efficacy and preempt liabilities
Confidential & Proprietary
3

**Layout**

Single-column bulleted list left-aligned at a left margin of about 7.5% of slide width, with the title sitting top-left below the logo. The logo sits top-left, the title is directly beneath it, and the bullet list fills the middle band. The footer 'Confidential & Proprietary' and slide number '3' sit bottom-right on one baseline, with a blank gap between the fifth-but-one and last bullet.

**Visuals**

A binary-code (0s and 1s) decorative graphic in blue: a broad band fading from dark blue at top-right to white toward the left across the top edge, and a second band in the bottom-left corner fading from light blue at the bottom-left to white toward the right. No charts, photos, or diagrams. The Theranos wordmark logo in green serif letters with a trademark mark at top-left.

**Design**

Background: White #FFFFFF with blue binary-code gradient bands at top-right and bottom-left. White background with blue binary-code banners at top-right and bottom-left. Title colour is a medium blue #1A6FA0, body text is dark grey #3A3A3A, bullet glyphs are blue #2E6DA4 diamond-cross symbols (❖). Title and body appear to be a sans-serif similar to Arial/Helvetica, regular weight; title is about 4.5% of slide height and body text about 3.6% of slide height. Lines are plain with no shapes or borders; no corner radii, shadows or gradients on text elements.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- illustration at x 27, y 5, w 73, h 14 [#3B7FCB]: Top-right binary-code band: blue (#3B7FCB to white gradient) field of 0s and 1s fading leftward (Gradient fades from dark blue at right edge to transparent white toward left; sits behind title area and logo; no border)
- illustration at x 4, y 80, w 58, h 14 [#7FB3E0]: Bottom-left binary-code band: light blue field of 0s and 1s fading to white toward right (Gradient from light blue at bottom-left to white at right; no border)
- logo at x 6.5, y 6.5, w 20, h 6.5 [#3E9B5A]: Theranos logo wordmark with trademark symbol TM (Green (#3E9B5A) serif wordmark with outlined letters; TM symbol small at upper-right)
- title at x 7.5, y 16, w 35, h 6 [Arial, regular; font size 4.5% of slide height; #1A6FA0; left aligned]: Theranos Today
- bullet list at x 7.5, y 23, w 88, h 47 [Arial, regular; font size 3.6% of slide height; #3A3A3A; left aligned]: 6 Deals, 5 companies: $6-12M for validation phase / 6 Phase IVs: $20-$50M each / $120 - $300M revenue in next 1.5 years / 10 companies and 1 government agency: 15 additional deals / $21-52M for validation / $300-$750M for phase IVs / Existing deals: $120M - $1.5Bn in revenue / (blank line) / Improve label, validate efficacy and preempt liabilities (Bullet glyph is a blue (#2E6DA4) four-petal diamond cross ❖; line spacing about 1.9 lines; blank gap between 'Existing deals' and 'Improve label' bullets)
- footer at x 71, y 94, w 16, h 2 [Arial, bold; font size 1.6% of slide height; #7A7A7A; right aligned]: Confidential & Proprietary (Small bold grey text)
- page number at x 91, y 93.5, w 2, h 3.5 [Arial, regular; font size 3.6% of slide height; #7A7A7A; right aligned]: 3

### Slide 4

**Review notes**

- Review: But the deck runs mostly as unvarying bullet lists with tiny type on slides 4 and 21, and the route is muddled: management comes at slide 4 before the product is shown, the value proposition appears twice (slides 9 and 16), and the offering and investor slides sit before a technology slide at the end.
- Suggested repair: Fix the text colliding with the footer band on slides 22 and 23, enlarge or split the dense management and investor lists on slides 4 and 21, and cut the chart on slide 13 down to a readable message.

**Text**

Theranos
Management
Elizabeth Holmes, President and CEO
Left Stanford Chemical and Electrical Engineering to found Theranos, also Genencor, Genome Institute Singapore
Howard Bailey, CFO
Former CFO who took QED and Photon Dynamics public, also CFO Occam, C-Cube, and Controller, Intel
Diane Parks, CCO
Former Senior Vice President, Biotherapeutics and Managed Care, Genentech, also Vice President, Marketing, Aventis
John Howard, Senior VP, Products
Former President, Panasonic Semiconductor, also President, IBM Microelectronics Division
Dr. Ian Gibbons, Senior Director Assay Development
Former Senior Director, Syva, ACLARA, Biotrack, AmCell, First Medical
Tim Kemp, Senior Director Informatics Systems
Former lead systems engineer, IBM, Embedded Systems
Board of Directors:
Donald L. Lucas, Chairman of the Board
46-year veteran of the venture capital business
Elizabeth Holmes
CEO, Theranos
Peter Thomas
Founder and Managing Director, ATA Ventures; General Partner, Institutional Venture Partners
Channing Robertson
Stanford Senior Associate Dean of Engineering
Confidential & Proprietary
4

**Layout**

Single-column layout with the title Management left-aligned near the top at about 13% from the left edge, followed by a bulleted two-level list of executives and a Board of Directors section in the lower half. A binary-code banner sweeps across the top right and a faded binary strip sits at the bottom left; the footer 'Confidential & Proprietary' sits bottom right with the slide number 4 at the far right, both near the bottom margin.

**Visuals**

Logo: the green 'Theranos' wordmark with a TM mark at top left, rendered in a serif display face with a caduceus-like staff in the T. Decorative banner top right: a blue gradient field of binary digits (0s and 1s) fading from saturated blue at the right edge to white toward the left, tapering diagonally down-left. Decorative strip bottom left: a faded blue binary-digit band fading from left to right into white, approximately 0 to 62% width and 83% to 100% height. No photographs, charts or tables.

**Design**

Background: White #FFFFFF with blue binary-digit gradient bands at top right and bottom left. White background with blue binary-code gradient bands at top right and bottom left. Title in bold sans-serif (Arial Bold style) in blue #1A6FA8, about 6.5% of slide height for capitals. Body text in regular Arial-style sans-serif, dark grey #333333, about 2.6% of slide height. Board of Directors heading in bold dark grey #333333. Bullets are blue arrowhead glyphs (Wingdings-style arrow) #2A7FC1 at first level and dark grey at second level. Footer in bold grey #808080 small sans-serif. Logo in green #3E9A5A. No shapes, borders or shadows.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- logo at x 6.8, y 6, w 20, h 8 [Serif display; #3E9A5A; left aligned]: Theranos wordmark logo in green with TM mark (Green outlined serif wordmark with caduceus-like staff in the T; TM superscript at upper right)
- shape at x 27, y 4.5, w 73, h 14 [#2F7FCB]: Binary-code gradient banner, top right (Blue gradient from saturated blue at right to transparent white at left, tapering diagonally; overlaps top edge of slide)
- title at x 7.5, y 16.5, w 24, h 6.5 [Arial, bold, sentence case; font size 6.5% of slide height; #1A6FA8; left aligned]: Management
- bullet list at x 12, y 19, w 83, h 35 [Arial, regular; font size 2.6% of slide height; #333333; left aligned]: Elizabeth Holmes, President and CEO / Left Stanford Chemical and Electrical Engineering to found Theranos, also Genencor, / Genome Institute Singapore / Howard Bailey, CFO / Former CFO who took QED and Photon Dynamics public, also CFO Occam, C-Cube, and / Controller, Intel / Diane Parks, CCO / Former Senior Vice President, Biotherapeutics and Managed Care, Genentech, also Vice / President, Marketing, Aventis / John Howard, Senior VP, Products / Former President, Panasonic Semiconductor, also President, IBM Microelectronics Division / Dr. Ian Gibbons, Senior Director Assay Development / Former Senior Director, Syva, ACLARA, Biotrack, AmCell, First Medical / Tim Kemp, Senior Director Informatics Systems / Former lead systems engineer, IBM, Embedded Systems (Level-1 items with blue arrowhead bullets, level-2 items indented with arrowhead bullets; line spacing about 1.0; no bullet for wrapped continuation lines)
- bullet list at x 12, y 54.5, w 75, h 27 [Arial, regular with bold heading; font size 2.6% of slide height; #333333; left aligned]: Board of Directors: / Donald L. Lucas, Chairman of the Board / 46-year veteran of the venture capital business / Elizabeth Holmes / CEO, Theranos / Peter Thomas / Founder and Managing Director, ATA Ventures; General Partner, Institutional Venture Partners / Channing Robertson / Stanford Senior Associate Dean of Engineering (Heading 'Board of Directors:' in bold; items with arrowhead bullets in blue at level 1, grey at level 2)
- footer at x 71.5, y 88.5, w 15.5, h 2.5 [Arial, bold; font size 1.8% of slide height; #808080; right aligned]: Confidential & Proprietary
- page number at x 91, y 88.5, w 2, h 3 [Arial, regular; font size 3% of slide height; #808080; right aligned]: 4
- shape at x 4.5, y 83, w 57, h 17 [#3A86CF]: Binary-code gradient strip, bottom left (Faded blue binary digits fading to white toward the right, overlapping the lower-left corner; no border)

### Slide 5

**Text**

Theranos / What is our system? / www.theranos.com / Confidential & Proprietary / 5

**Layout**

Free-form layout with the logo top-left and the title beneath it, left-aligned at about x 7.75%. A 3-column photo strip sits in the upper row and a photo plus a chart form the lower row, centred in the slide with margins of about 13% left and 16% right. The URL is centred below the image block, and the footer 'Confidential & Proprietary' and page number '5' sit at bottom right.

**Visuals**

Four photographs and one line chart. Photo 1 (top-left): a hand holding a white rectangular plastic card labelled 'Theranos 1.0' with chevron arrows and a red arrow reading 'Place sample here', against a dark wooden surface. Photo 2 (top-middle): a hand holding a translucent white cartridge with a blue glowing light at its left edge and faint channel traces, against a dark background. Photo 3 (top-right): a beige-grey boxed device labelled 'Theranos' with a green LED and red LED on its front face and a sample slot, its open top showing green circuit boards, on a light lavender-grey background. Photo 4 (bottom-left): a hand holding a device with a green circuit board, two white LEDs, stacked transparent acrylic plates and a white ruler above it, on a light grey-white background. Chart (bottom-right): line chart with no title, on a white box with thin grey border. Y-axis 'Bound Label (M)' from 0 to 1.2E-10 with ticks 0, 2E-11, 4E-11, 6E-11, 8E-11, 1E-10, 1.2E-10. X-axis 'Concentration (M)' is logarithmic from 1.00E-12 to 1.00E-08 with a tick each decade. Series 'Competitive' (dark teal-green line): about 7.3E-11 flat at the left, falling gradually through about 4E-11 near 1.00E-10 and reaching about 0 near 1.00E-08. Series 'Two Step' (gold-orange line): about 1.1E-10 at the left, dropping steeply near 5E-11 and reaching about 0 by about 1.00E-09. Legend box at upper right of plot with entries 'Competitive' (green) and 'Two Step' (orange). No highlighted points. Photos are boxed and sharp-edged with no overlay. The top-right and bottom-left binary-code banners are decorative blue gradient graphics, not photos.

**Design**

Background: White #FFFFFF with blue binary-code gradient banners at top-right and bottom-left. White background with a blue binary-digit (0 and 1) streak fading across the top-right and bottom-left corners. Title in blue #1F6FA8, regular Arial-style sans-serif, about 4.5% of slide height. URL in near-black #222222, Arial regular, underlined, about 3.9% of slide height. Footer 'Confidential & Proprietary' in bold grey #7F7F7F, Arial, about 2% of slide height. Page number in grey #808080, Arial, about 3.5% of slide height. Photos and chart box have sharp corners, no shadows, and thin grey edges on the chart box.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 45, y 5.8, w 50, h 13 [#3A7BC8]: Decorative blue binary-code banner, top-right, fading to white toward the left and bottom (Gradient from saturated blue #2F6FBF at the right edge to transparent white at the left; made of rows of 0 and 1 digits)
- logo at x 6.75, y 7.8, w 19.75, h 5.2 [#2E8B6A]: Theranos logo with TM mark (Green serif wordmark 'Theranos' with a caduceus-like staff in the T, followed by a small superscript TM)
- title at x 7.75, y 14.4, w 27.4, h 3.9 [Arial regular, sentence case; font size 4.5% of slide height; #1F6FA8; left aligned]: What is our system?
- photo at x 12.9, y 23.5, w 25.2, h 23.5 [#5A3A2A]: Photo: hand holding white Theranos 1.0 card with chevrons and 'Place sample here' arrow, dark wood background (Boxed, rectangular, sharp corners, no overlay)
- photo at x 37.9, y 23.5, w 25.2, h 23.5 [#1E2430]: Photo: hand holding translucent cartridge with blue glowing light, dark background (Boxed, rectangular, sharp corners, no overlay)
- photo at x 62.2, y 23.5, w 23.9, h 23.6 [#D8D2D0]: Photo: beige boxed Theranos device with green and red LEDs and open top showing circuit boards (Boxed, rectangular, sharp corners, no overlay)
- photo at x 12.9, y 47.2, w 36.6, h 30.1 [#E6E6E6]: Photo: hand holding metal and acrylic device with circuit board, LEDs and white ruler above (Boxed, rectangular, sharp corners, no overlay)
- chart at x 49.7, y 46.7, w 35.3, h 30.4 [#FFFFFF]: Line chart, Bound Label (M) vs Concentration (M), series Competitive and Two Step (White box with thin grey border; y-axis 0 to 1.2E-10; x-axis log 1.00E-12 to 1.00E-08; legend box at upper right with grey border; Competitive line #1E7B5A, Two Step line #E8A317)
- body at x 39.5, y 81.2, w 21, h 4.5 [Arial, regular, lowercase, underlined; font size 3.9% of slide height; #222222; center aligned]: www.theranos.com (Hyperlink styling with single underline)
- shape at x 4.5, y 83, w 58, h 12.5 [#4A86C8]: Decorative blue binary-code banner, bottom-left, fading to white toward the right and top (Gradient of binary digits from blue at the bottom-left to transparent white at upper right)
- footer at x 71.7, y 88.6, w 14, h 2.2 [Arial, bold; font size 2% of slide height; #7F7F7F; left aligned]: Confidential & Proprietary
- page number at x 91, y 88.8, w 1.8, h 3.5 [Arial, regular; font size 3.5% of slide height; #808080; right aligned]: 5

### Slide 6

**Review notes**

- Worth studying: Places a technology diagram beside the product diagram to show how cartridge, reader and informatics fit together.
- Review: Several pages have fit and legibility defects: the caption on slide 22 collides with the footer band, slide 23 text overlaps the footer, the chart on slide 13 has overprinted axis labels and unreadable noise, and slide 6 pairs unlabeled drawings with a stock server photo and no explanation.
- Worth keeping: Keep the three-step chemotherapy chart sequence on slides 10 to 12 with its one-sentence takeaway under each chart, and the cartridge, reader, informatics flow on slide 6 as a simple product map.

**Text**

Theranos
Technology
Theranos Products
Cartridge
Reader
Informatics
Reagents
Control
Wash 1
Amp
Wash 2
Label 1
Label 2
Push
Test Sites
Motion
Waste Valves
Vacuum Pump
Vacuum Sensor
Mixing
Waste 1
Waste 2
Multiplex Vent Valve
Sample Vent Valve
Separator
Metering
Sample Port
Theranos
Confidential & Proprietary
6

**Layout**

Full-width slide with the Theranos logo top-left and the title Technology left-aligned at the top-left margin, with Theranos Products placed above the right-hand boxed group. A large rounded-corner outline frame spans the centre-right of the slide, containing the three-stage flow Cartridge, Reader, Informatics; a column of three technology illustrations sits to the left of the frame, joined by a curved bracket. Footer text Confidential & Proprietary sits bottom-right with page number 6 at the far right; binary-code bands run across the top right and bottom left.

**Visuals**

Left column of three illustrations, top to bottom: (1) an antibody-style diagram of two red circles with blue Y-shaped antibody pairs on a horizontal baseline with small stalks, about 40 percent of its width in red and blue; (2) a grey microfluidic cartridge schematic on a vertical stand with labelled reagent wells (Reagents, Control, Wash 1, Amp, Wash 2, Label 1, Label 2, Push, Mixing, Separator, Metering, Waste 1, Waste 2), valves (Multiplex Vent Valve, Sample Vent Valve, Vacuum Sensor, Vacuum Pump, Waste Valves), Test Sites and Motion arrow, and Sample Port; (3) an exploded view of four stacked grey-outlined cartridge plates with holes and channels. A curved black bracket connects this column to the frame. Inside the frame: a photograph of a hand holding a white Theranos cartridge card with small text Theranos and blue indicator dots, shown in front of a stack of three orange-red cartridge sheets, cropped as a rectangle with a soft shadow; a black arrow points right to a dark navy and grey rectangular benchtop reader box with a light grey front display strip and round knob; a black arrow points from the reader toward a boxed photograph of a large dark grey server cabinet array in a clean data centre, with a blue-panel module in the middle and rows of server racks on the right, lit by overhead white light with a white floor, framed with a thin light border; three black arrows point down from the photo to three flat-screen monitors on black stands showing purple-and-white software windows with blue and teal panels, placed side by side.

**Design**

Background: White #FFFFFF with blue binary-code bands at top right and bottom left. Clean white background with blue binary-code bands (#2F6FB5 to pale #DDE9F5 gradient) across the top right and bottom left. Title and heading text in medium blue #1A6A9A, Arial-style sans-serif regular weight, about 5 percent of slide height for Technology and Theranos Products. Labels Cartridge, Reader and Informatics in dark grey #333333 Arial regular, about 3.5 percent of slide height. Footer Confidential & Proprietary in bold grey #6D6E71 Arial, about 1.8 percent of slide height. Page number in light grey #808080 Arial, about 2.8 percent. Logo in green #3A9A5B serif-style wordmark with a small trademark mark. Rounded outline frame in thin charcoal #3A3A3A stroke about 0.2 percent of width with a large corner radius; no fill. Arrows are thin black #1A1A1A lines with small filled heads. Orange cartridge sheets #F26D4F with dark outlines; reader in navy #2D3E6B with grey #5A5F66 top.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- logo at x 6.5, y 6.5, w 20.5, h 7.5 [#3A9A5B]: Theranos wordmark logo with TM mark, green serif lettering (Top-left corner, sits above Technology title)
- shape at x 27, y 5, w 68, h 16 [#2F6FB5]: Blue binary-code band top right, fading to white toward the left (Background pattern image, behind title area, low opacity fade)
- shape at x 4.5, y 82, w 58, h 18 [#2F6FB5]: Blue binary-code band bottom left, fading to white toward the right (Background pattern image, low opacity fade)
- title at x 7.5, y 17, w 22, h 6.5 [Arial regular sans-serif; font size 5% of slide height; #1A6A9A; left aligned]: Technology
- title at x 48, y 17, w 31, h 6.5 [Arial regular sans-serif; font size 5% of slide height; #1A6A9A; left aligned]: Theranos Products
- illustration at x 10, y 34, w 11, h 10 [#D62B2B]: Antibody diagram: two red circles with blue Y-shaped antibodies on baseline with stalks (Line art with blue #2F5FD0 fills)
- illustration at x 9.5, y 45.5, w 13, h 16 [#D9D9D9]: Microfluidic cartridge schematic with labelled reagent wells and valves on grey #D9D9D9 panel (Small labels in black Arial, wells in yellow, orange, pink, teal, blue)
- illustration at x 11, y 64, w 10, h 15 [#FFFFFF]: Exploded view of four stacked cartridge plates with holes (Thin grey outlines on white)
- line at x 24, y 36, w 3.5, h 32 [#1A1A1A]: Curved black bracket joining left illustration column to frame (Stroke about 0.2 percent of width)
- shape at x 28.8, y 23.5, w 66.5, h 53 [#FFFFFF]: Rounded rectangle frame enclosing product flow (Outline only, charcoal #3A3A3A stroke, large corner radius, no fill)
- photo at x 29.5, y 48.5, w 10.5, h 12.5 [#F26D4F]: Hand holding white Theranos cartridge card with blue indicator dots, in front of orange cartridge stack (Rectangular crop, soft shadow, hand skin tone and white card)
- shape at x 29.5, y 51, w 10, h 12 [#F26D4F]: Stack of three orange-red cartridge sheets with dark outlines (Overlapping offset sheets behind photo)
- line at x 40.5, y 52.5, w 4, h 1.5 [#1A1A1A]: Black arrow from cartridge to reader (Thin line with filled arrowhead)
- illustration at x 47, y 46, w 8, h 9 [#2D3E6B]: Benchtop reader box, navy and grey 3D rectangle with display strip and round knob (Grey #5A5F66 top and front strip)
- line at x 58.5, y 45, w 2.5, h 1.5 [#1A1A1A]: Black arrow from reader toward server photo (Thin line with filled arrowhead)
- photo at x 61, y 26.5, w 29, h 27 [#4A4A4A]: Data centre with large dark grey server cabinet, blue-panel module, and rows of server racks (Boxed rectangle with thin light grey border, slight cream tint, overhead white light)
- line at x 63, y 53.5, w 21, h 5 [#1A1A1A]: Three black arrows from server photo down to monitors (Thin lines with filled arrowheads)
- illustration at x 63.5, y 56.5, w 7.5, h 12 [#2B2B2B]: Monitor 1 on black stand showing purple software windows (Silver bezel, purple and blue screen)
- illustration at x 73, y 56.5, w 7.5, h 12 [#2B2B2B]: Monitor 2 on black stand showing purple software windows (Silver bezel, purple and blue screen)
- illustration at x 82, y 56.5, w 7.5, h 12 [#2B2B2B]: Monitor 3 on black stand showing purple software windows (Silver bezel, purple and blue screen)
- caption at x 32, y 69.5, w 9.5, h 3.5 [Arial regular sans-serif; font size 3.5% of slide height; #333333; left aligned]: Cartridge
- caption at x 46.5, y 69.5, w 8.5, h 3.5 [Arial regular sans-serif; font size 3.5% of slide height; #333333; left aligned]: Reader
- caption at x 70.5, y 69.5, w 12.5, h 3.5 [Arial regular sans-serif; font size 3.5% of slide height; #333333; left aligned]: Informatics
- footer at x 71.5, y 88.5, w 14.5, h 2.5 [Arial bold sans-serif; font size 1.8% of slide height; #6D6E71; left aligned]: Confidential & Proprietary
- page number at x 91, y 88.5, w 1.5, h 3 [Arial regular sans-serif; font size 2.8% of slide height; #808080; right aligned]: 6

### Slide 7

**Text**

Theranos ABCS™: Ambulatory BioInformatics
Communications System
Pharmacy
Partner
HMO
Theranos Informatics
Home
Telecommunications
Videoconferencing
Effective narrow range therapy through post-prescription
monitoring of the total available patient base.
Confidential & Proprietary
7

**Layout**

Free-form diagram on a white field with a centred bold title at top and a large body statement along the lower-left. The Theranos logo sits top-left and the footer with page number 7 sits bottom-right. A blue binary-code band runs across the top right and a faded blue binary-code band across the bottom left, with the content left-aligned near a 7% left margin.

**Visuals**

Diagram with five labelled parts. A green arrow (about 15% of slide width) points left from Partner (grey stacked-block building illustration, upper right) to a brown pill bottle labelled Pharmacy, which has Rx mortar and caduceus icons beneath its label. A vertical green arrow points down from Pharmacy, labelled HMO, to a line-drawn house labelled Home containing a white Theranos device (rounded dome unit with a small red and green indicator) and captions Telecommunications and Videoconferencing beside it. A line-drawn office building with a standing doctor in white coat and stethoscope pointing to a clipboard sits above the house, joined to it by short dashed grey lines. Grey dashed lines radiate from Partner and the office building to a photograph at lower right of a server room: dark grey-brown cabinets with a blue-lit control panel in the centre and rows of grey server racks at right, photographed straight-on, full colour, boxed with a hard rectangular edge, cool white ceiling lighting, no overlay. Labelled Theranos Informatics above the photo.

**Design**

Background: White (#FFFFFF) with blue binary-code gradient bands at top right and bottom left.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- background band at x 25, y 4, w 75, h 14: Blue binary-code gradient band across top right, fading to white toward the left (Blue #3A7BC8 digits on pale blue fading to white)
- logo at x 7, y 7, w 19, h 6 [#2E8B57]: Theranos logo: green serif wordmark with a caduceus over the T and a small TM mark
- title at x 15, y 13, w 67, h 10 [Arial, bold; font size 4.2% of slide height; #00639A; center aligned]: Theranos ABCS™: Ambulatory BioInformatics / Communications System
- body at x 17, y 18, w 13, h 4 [Arial, bold; font size 3.2% of slide height; #0E6E5A; left aligned]: Pharmacy
- icon at x 20, y 25, w 6, h 4 [#1F4E79]: Rx mortar and pestle icon and caduceus icon (Thin dark line icons)
- illustration at x 30, y 23, w 5, h 14 [#8B3E1C]: Brown pill bottle with white screw cap and beige label band
- body at x 68, y 19, w 9, h 4 [Arial, bold; font size 3.2% of slide height; #0E6E5A; left aligned]: Partner
- illustration at x 52, y 18, w 14, h 16 [#A59E97]: Stacked grey office block illustration with rows of windows, viewed from above at an angle
- shape at x 36, y 29, w 15, h 2 [#2E9B55]: Green arrow pointing left from Partner to Pharmacy bottle (Solid line about 0.4% of slide height thick with filled triangular arrowhead at left end)
- body at x 14, y 33, w 9, h 4 [Arial, bold; font size 3.2% of slide height; #0E6E5A; left aligned]: HMO
- shape at x 23, y 35, w 1, h 20 [#2E9B55]: Vertical green arrow pointing down from Pharmacy to Home (Solid line with filled triangular arrowhead at bottom)
- illustration at x 27, y 39, w 14, h 10 [#FFFFFF]: Line-drawn office building with grid of windows and a door (Thin black outline, white fill)
- illustration at x 34, y 42, w 6, h 10 [#FFFFFF]: Standing doctor in white coat with stethoscope, pointing to a clipboard (Brown trousers, white coat)
- line at x 22, y 31, w 37, h 30 [#9A9AA8]: Dashed grey connector lines from Partner and office building to the server photo and from building to house (Grey dashes about 0.3% of slide height stroke, several parallel dashed strokes)
- body at x 59, y 44, w 27, h 4 [Arial, bold; font size 3.2% of slide height; #0E6E5A; left aligned]: Theranos Informatics
- photo at x 59, y 50, w 29, h 26 [#4A4550]: Server room photograph: dark cabinets with blue-lit control panel and rows of grey server racks (Boxed, rectangular, not cropped, full colour, no overlay)
- illustration at x 22, y 55, w 21, h 18 [#FFFFFF]: Line-drawn house with pitched roof, chimney, door and porch (Thin black outline, white fill)
- illustration at x 33, y 64, w 8, h 8 [#E8EEE8]: Theranos home device: white rounded dome unit with Theranos wordmark and small red and green indicators
- body at x 16, y 61, w 9, h 4 [Arial, bold; font size 3.2% of slide height; #0E6E5A; left aligned]: Home
- caption at x 42, y 65, w 14, h 6 [Arial, regular; font size 2.2% of slide height; #222222; left aligned]: Telecommunications / Videoconferencing
- body at x 8, y 76, w 80, h 9 [Arial, regular; font size 4.6% of slide height; #333333; left aligned]: Effective narrow range therapy through post-prescription / monitoring of the total available patient base. (Line spacing about 1.1)
- footer at x 71, y 88, w 13, h 2.5 [Arial, bold; font size 1.8% of slide height; #666666; right aligned]: Confidential & Proprietary
- page number at x 91, y 88, w 2, h 3 [Arial, regular; font size 3.2% of slide height; #666666; right aligned]: 7

### Slide 8

**Text**

Product Features
Use: Simultaneous quantitative measurement of drugs and treatment-related biomarkers
Sample Size: 5-10µL of blood
Time: Multiplex assays complete in < 30 minutes
Calibration/Control: On board with each measurement
Operating Principle: Chemiluminescent/Immunoassay
Dynamic Range: Low picogram/mL – high microgram/mL
Accuracy: Results comparable to “gold standards”
Precision: Average total 5-7% Coefficient of Variation or better
Data Reporting: Immediate upload from secured server
Attractiveness: New assays can be developed and implemented within about three months and can be fully developed at ISO 9000 standards within about six months.
Confidential & Proprietary
8

**Layout**

Single-column layout on a white field with the logo at top left, the title left-aligned below it, and a bulleted list filling the body from the title to the lower footer band. The footer text 'Confidential & Proprietary' sits at lower right with the slide number at the far right, on the same baseline.

**Visuals**

Two decorative binary-code illustrations, not photographs: a blue-tinted band across the top right, fading to white toward the left, and a blue-tinted band across the bottom left, fading to white toward the right. Both bands are full-bleed to their corners and show rows of 0 and 1 digits in white and light blue on a medium-blue gradient. The Theranos logo is a green serif wordmark with a small caduceus-like emblem and a trademark TM mark at its upper right. No charts, tables or photographs.

**Design**

Background: White #FFFFFF with blue binary-code illustration bands at top right and bottom left. White background with blue binary-code bands at top right and bottom left. Title in Arial-style regular sans-serif, blue #1B6E9E, about 4.2% of slide height. Body text in Arial-style regular sans-serif, dark grey #3A3A3A, about 3.4% of slide height, with bullet lead-in labels in blue #1B6E9E. Bullets are blue #1B6E9E diamond glyphs. Footer text is bold Arial-style sans-serif in grey #6E6E6E, about 1.6% of slide height. Slide number is regular grey #7F7F7F. No shadows, rounded corners or gradients on shapes.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- illustration at x 26, y 5, w 69, h 14: Top-right binary-code band fading to white toward the left (Full-bleed to top-right area, blue gradient #3E7FC4 to white, rows of 0/1 digits, sits behind the title region without overlapping text)
- illustration at x 4, y 82, w 58, h 12: Bottom-left binary-code band fading to white toward the right (Blue gradient with light blue and white 0/1 digits, sits behind footer area at left, no overlap with text)
- logo at x 6.5, y 7.5, w 20, h 6.5 [#3A9A5B]: Theranos logo with TM mark (Green serif wordmark with caduceus emblem; TM superscript at upper right of wordmark)
- title at x 7.5, y 15, w 26, h 5 [Arial regular, sans-serif, normal case; font size 4.2% of slide height; #1B6E9E; left aligned]: Product Features
- bullet list at x 11, y 24, w 80, h 58 [Arial regular, sans-serif, normal case; font size 3.4% of slide height; #3A3A3A; left aligned]: ❖ Use: Simultaneous quantitative measurement of drugs and / treatment-related biomarkers / ❖ Sample Size: 5-10µL of blood / ❖ Time: Multiplex assays complete in < 30 minutes / ❖ Calibration/Control: On board with each measurement / ❖ Operating Principle: Chemiluminescent/Immunoassay / ❖ Dynamic Range: Low picogram/mL – high microgram/mL / ❖ Accuracy: Results comparable to “gold standards” / ❖ Precision: Average total 5-7% Coefficient of Variation or better / ❖ Data Reporting: Immediate upload from secured server / ❖ Attractiveness: New assays can be developed and implemented / within about three months and can be fully developed at ISO 9000 / standards within about six months. (Diamond bullets in blue #1B6E9E; lead-in labels Use, Sample Size, Time, Calibration/Control, Operating Principle, Dynamic Range, Accuracy, Precision, Data Reporting and Attractiveness in blue #1B6E9E; line spacing about 1.3; each bullet is a separate paragraph with about 0.6 line gap between bullets)
- footer at x 71.5, y 88.5, w 16.5, h 2.2 [Arial bold, sans-serif, normal case; font size 1.6% of slide height; #6E6E6E; right aligned]: Confidential & Proprietary
- page number at x 91, y 89.5, w 2.5, h 2.5 [Arial regular, sans-serif, normal case; font size 2.6% of slide height; #7F7F7F; right aligned]: 8

### Slide 9

**Review notes**

- Review: But the deck runs mostly as unvarying bullet lists with tiny type on slides 4 and 21, and the route is muddled: management comes at slide 4 before the product is shown, the value proposition appears twice (slides 9 and 16), and the offering and investor slides sit before a technology slide at the end.
- What would change the score: I would reorder to problem, solution, product, evidence, market, team, offering, and turn the bullet-only slides 3, 9, 16, 17 and 18 into fewer, headline-led pages with a clear point each.

**Text**

Value Proposition
Increase pharmaceutical sales by improving the label of a compound
Remove black boxes
Safely sell to total available patient base
Introduce existing compounds to market (rather than relying heavily on gene sequencing and new discoveries)
Increase the number of patients enrolling in trials and reduce drop-outs
Increase compliance
Confidential & Proprietary
9

**Layout**

Single-column slide with the logo top-left and the title below it, left-aligned at about 8% margin. Bulleted body text sits in one column below the title, with a level-one bullet followed by four level-two bullets and one more level-two bullet. Footer text 'Confidential & Proprietary' sits bottom-right with the slide number 9 at the far right edge.

**Visuals**

Two decorative binary-code (0/1 digit) gradient bands: a blue band fading to white across the top-right corner from roughly the top edge to the title line, and a lighter blue band fading in from the bottom-left corner. The Theranos logo (green serif wordmark with a caduceus-like symbol and TM mark) at top-left. Bullet glyphs are blue arrowhead symbols. No photographs or charts.

**Design**

Background: White #FFFFFF with blue binary-code gradient bands at top-right and bottom-left. White background with blue binary-code gradient bands at top-right and bottom-left. Title in bold blue (#0A6EA8) sans-serif (Arial Bold-like), about 6% of slide height. Body text dark grey (#333333) Arial regular, about 3.6% of slide height for the level-one bullet and about 3.3% for level-two bullets. Bullet arrowheads in blue #1A6FB0. Footer text small bold grey (#777777) Arial. No shapes, lines, corner radii or shadows.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- illustration at x 27, y 5, w 73, h 17 [#4A8FD0]: Blue binary-code gradient band fading to white, top-right corner (Background decoration of 0 and 1 digits in light blue, fading to transparent toward the left and bottom.)
- illustration at x 5, y 82, w 63, h 12 [#6AA6DC]: Blue binary-code gradient band fading to white, bottom-left corner (Background decoration of 0 and 1 digits in light blue, fading to transparent toward the right and top.)
- logo at x 6.5, y 7.5, w 27, h 6.5 [#2E9E6A]: Theranos logo with TM mark (Green serif wordmark with a caduceus-like symbol integrated into the T, green outline.)
- title at x 7.5, y 17, w 41, h 6 [Arial, bold, sentence case; font size 6% of slide height; #0A6EA8; left aligned]: Value Proposition
- bullet list at x 7, y 31, w 88, h 40 [Arial, regular, sentence case; font size 3.5% of slide height; #333333; left aligned]: Increase pharmaceutical sales by improving the label of a / compound / Remove black boxes / Safely sell to total available patient base / Introduce existing compounds to market (rather than relying heavily / on gene sequencing and new discoveries) / Increase the number of patients enrolling in trials and reduce drop- / outs / Increase compliance (Level-one bullet: 'Increase pharmaceutical sales by improving the label of a compound'. Level-two bullets indented, each with blue arrowhead glyph (#1A6FB0), line spacing about 1.2, paragraph gap between items.)
- footer at x 71.5, y 88.5, w 17.5, h 2.5 [Arial, bold, sentence case; font size 1.8% of slide height; #777777; right aligned]: Confidential & Proprietary
- page number at x 91, y 88.5, w 2.5, h 3 [Arial, regular; font size 2.6% of slide height; #777777; right aligned]: 9

### Slide 10

**Review notes**

- Review: The core story of monitoring drug levels and adjusting dose is recoverable, and slides 10 to 12 show it in a clear before-and-after sequence with plain captions.
- Worth keeping: Keep the three-step chemotherapy chart sequence on slides 10 to 12 with its one-sentence takeaway under each chart, and the cartridge, reader, informatics flow on slide 6 as a simple product map.

**Text**

Theranos
First course of infusion chemotherapy with
Theranos monitoring
First course of treatment
(Drug level too high)
Parameter
First course dose
First course drug level
Drug level target
Time, hours
Standard dose rate; patient is not eliminating drug rapidly and drug
concentration increases over the target level to a toxic level.
Confidential & Proprietary
10

**Layout**

Single-column slide on white with the title at upper left under the Theranos logo, a boxed line chart centred in the upper-middle area, a two-line body statement left-aligned below the chart, and the footer and page number at lower right. Left margin about 7 percent of slide width; the chart box is centred with roughly 18 percent margins on each side.

**Visuals**

One line chart inside a thin grey bordered box. Title: First course of treatment / (Drug level too high), bold dark grey. Y axis labelled Parameter (rotated vertical, bold), range 0.0 to 3.0 in steps of 0.5, no units printed. X axis labelled Time, hours, range -2.0 to 7.0 in steps of 1.0, no units beyond hours. Series 1, First course dose: navy #2E2E6E line with diamond markers; about 0 at -1.0 and 0.0, about 1.05 at 0.5, about 1.0 at 1.0, 1.5, 2.0, about 1.05 at 2.5, about 1.0 at 3.0, about 0 at 3.5, 4.0, 5.0 and 6.0 (no values printed). Series 2, First course drug level: magenta #E6007E line with square markers; about 0.0 at -1.0 and 0.0, about 0.72 at 0.5, about 1.52 at 1.0, about 2.5 at 1.5, about 2.72 at 2.0 (peak), about 2.42 at 2.5, about 2.22 at 3.0, about 1.52 at 3.5, about 1.22 at 4.0, about 1.02 at 5.0, about 0.92 at 6.0 (no values printed). Series 3, Drug level target: red #FF0000 line with triangle markers at 1.0 for x = 0.5, 1.0, 1.5, 2.0, 2.5, 3.0. Legend box at upper right inside the plot area with three entries: First course dose, First course drug level, Drug level target, each with its marker and line swatch. No highlighted points.

**Design**

Background: White #FFFFFF with blue binary-code texture bands at top right and bottom left fading to white. White background with blue binary-code texture bands at top right and bottom left. Title and footer colour steel blue #1A6A9A for title and dark grey #6E6E6E for footer. Body text dark charcoal #333333. Logo green #3A9E6F. Typeface Arial/Helvetica style sans-serif; title bold, body regular, footer bold; title about 5.5 percent of slide height, body about 3.8 percent. Chart uses plain Excel-like styling with thin grey axes and no gridlines. Square corners, no shadows or gradients on chart.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- photo at x 27, y 5.5, w 68, h 14 [#3D7CC9]: Blue binary-code texture band (digits 0 and 1 on blue gradient) across the top right (Fades from saturated blue at right to white at left; sits behind the title's right end; full-bleed to top and right edges.)
- photo at x 4.5, y 83, w 58, h 12 [#8FB3E0]: Blue binary-code texture band across the bottom left (Light blue digits fading to white toward the right; sits behind the bottom-left of the body text area; full-bleed to left edge.)
- logo at x 6.8, y 7.5, w 19.5, h 6.5 [#3A9E6F]: Theranos wordmark with TM superscript, green serif-style lettering (Green outlined wordmark with a stylised staff motif in the T; TM mark at top right of the wordmark.)
- title at x 7, y 12.5, w 85, h 13 [Arial, bold, sentence case, no letter-spacing; font size 5.5% of slide height; #1A6A9A; left aligned]: First course of infusion chemotherapy with / Theranos monitoring (Two lines, line spacing about 1.1.)
- chart at x 18.6, y 26, w 57.8, h 47.4 [#FFFFFF]: Line chart titled First course of treatment (Drug level too high) with three series and legend (Boxed with thin grey #808080 border 0.75 pt; plot area border grey; legend box at upper right of plot with white fill and grey border; series lines about 1.5 pt with markers about 6 px.)
- caption at x 9, y 75.5, w 82, h 10 [Arial, regular, sentence case; font size 3.8% of slide height; #333333; left aligned]: Standard dose rate; patient is not eliminating drug rapidly and drug / concentration increases over the target level to a toxic level. (Two lines, line spacing about 1.2.)
- footer at x 71.7, y 88.8, w 14.5, h 2.2 [Arial, bold, sentence case; font size 1.8% of slide height; #6E6E6E; left aligned]: Confidential & Proprietary
- page number at x 90.2, y 88.5, w 3, h 3.2 [Arial, regular; font size 3.3% of slide height; #6E6E6E; left aligned]: 10

### Slide 11

**Review notes**

- Worth studying: Repeats the chart layout of slide 10 with the same axes so the reduced-dose result can be compared directly.
- Review: The core story of monitoring drug levels and adjusting dose is recoverable, and slides 10 to 12 show it in a clear before-and-after sequence with plain captions.
- Worth keeping: Keep the three-step chemotherapy chart sequence on slides 10 to 12 with its one-sentence takeaway under each chart, and the cartridge, reader, informatics flow on slide 6 as a simple product map.

**Text**

Theranos™ / Second course of infusion chemotherapy with / Theranos monitoring / Second course (Drug dose reduced) / Parameter / 3.0 / 2.5 / 2.0 / 1.5 / 1.0 / 0.5 / 0.0 / -2.0 / -1.0 / 0.0 / 1.0 / 2.0 / 3.0 / 4.0 / 5.0 / 6.0 / 7.0 / Time, hours / Second course dose / Second course drug level / Drug level target / Same patient, second course of therapy; dose is lowered based / on Theranos results >> drug level is at target. / Confidential & Proprietary / 11

**Layout**

Single content slide with a left-aligned title block at the top, a centred bordered chart in the middle, and a left-aligned body sentence below the chart. The Theranos logo sits top-left, the binary-code banner runs across the top-right, and the footer 'Confidential & Proprietary' with page number 11 sits bottom-right above a binary-code band in the bottom-left corner. Margins are about 7% on the left and 8% on the right.

**Visuals**

Line chart titled 'Second course (Drug dose reduced)' inside a thin grey rectangular frame. X axis 'Time, hours' from -2.0 to 7.0 with tick labels at -2.0, -1.0, 0.0, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0. Y axis 'Parameter' from 0.0 to 3.0 in steps of 0.5. No gridlines; plot area has a thin grey border. Series 1 'Second course dose' is a navy line (#2E2A5C) with dark navy diamond markers: about 0 at -1.0 and 0.0, about 0.5 at 0.5 through 3.0 (plateau), about 0 at 3.5, 4.0, 5.0 and 6.0. Series 2 'Second course drug level' is a magenta-pink line (#E0218A) with magenta square markers: about 0 at -1.0 and 0.0, about 0.5 at 0.5, about 0.9 at 1.0, about 1.1 at 1.5, about 0.9 at 2.0, about 0.8 at 2.5, about 1.0 at 3.0, about 0.7 at 3.5, about 0.5 at 4.0, about 0.35 at 5.0, about 0.3 at 6.0. Series 3 'Drug level target' is a thin red line (#E01E1E) with red triangle markers at 1.0 on the y axis for x = 0.5, 1.0, 1.5, 2.0, 2.5 and 3.0. Legend box in the upper right of the plot area with white fill and thin grey border, listing the three series in the order above. No points are highlighted beyond the markers.

**Design**

Background: White (#FFFFFF) with blue binary-code banners at top-right and bottom-left.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- banner at x 27, y 5.8, w 68, h 13 [#3A7BD5]: Blue binary-code (0 and 1 digits) graphic fading to white, top-right corner (Full-width band fading out to the left, no border, behind the title area; bottom edge fades to white)
- banner at x 4.5, y 82, w 58, h 12 [#4A8AD8]: Blue binary-code graphic fading to white, bottom-left corner (Bottom-left band fading to white toward the right, sits behind the body text and footer area; body text overlaps its top edge)
- logo at x 6.8, y 7.8, w 19.8, h 5.2 [#2E9E6A]: Theranos wordmark in green serif lettering with a caduceus-like staff in the T, and a small TM mark (Green (#2E9E6A) outlined lettering with a darker green outline; TM superscript at top-right)
- title at x 7.7, y 17.8, w 83, h 11.5 [Arial, bold, sans-serif; font size 6.2% of slide height; #0E6A9A; left aligned]: Second course of infusion chemotherapy with / Theranos monitoring (Two lines, line spacing about 1.0; sits above the chart)
- chart at x 19.4, y 31.1, w 57.5, h 45.4 [#FFFFFF]: Line chart: Second course (Drug dose reduced), three series with markers, legend inside plot (Chart frame with thin grey (#8C8C8C) 0.75pt border and white fill; chart title bold dark grey (#404040) Arial about 2.2% of slide height; axis labels Arial about 1.9% in dark grey (#404040); plot area border grey; legend box white with grey border; series lines about 1.5pt; smoothed curves through markers)
- body at x 13.1, y 80.4, w 71, h 7.8 [Arial, regular, sans-serif; font size 3.6% of slide height; #333333; left aligned]: Same patient, second course of therapy; dose is lowered based / on Theranos results >> drug level is at target. (Two lines, line spacing about 1.2; sits over the bottom-left binary banner)
- footer at x 71.7, y 89, w 14, h 1.5 [Arial, bold, sans-serif; font size 1.6% of slide height; #6E6E6E; right aligned]: Confidential & Proprietary (Single line, sits left of the page number)
- page number at x 90.2, y 88.8, w 2.1, h 2.3 [Arial, regular, sans-serif; font size 2.6% of slide height; #6E6E6E; right aligned]: 11 (Right-aligned page number)

### Slide 12

**Review notes**

- Worth studying: Uses one chart and a short caption to show how a mid-course correction brings the drug level back to target.
- Review: The core story of monitoring drug levels and adjusting dose is recoverable, and slides 10 to 12 show it in a clear before-and-after sequence with plain captions.
- Worth keeping: Keep the three-step chemotherapy chart sequence on slides 10 to 12 with its one-sentence takeaway under each chart, and the cartridge, reader, informatics flow on slide 6 as a simple product map.

**Text**

Dose Customization
Drug dose adjusted in course
Parameter
First course, drug dose corrected in course
Drug level
Drug level target
Time, hours
Same patient but in the first course rapid (within one hour) feedback from Theranos monitor leads to a decision to stop the infusion. Drug level drops from toxic to target.
Confidential & Proprietary
12

**Layout**

Single-column slide on white with the title at upper left, below a Theranos logo at top left. A bordered chart sits centred below the title, with the body text left-aligned beneath it, starting at the same left edge as the title area. The footer confidentiality mark and page number sit at bottom right, with a binary-code banner across the top right and another across the bottom left.

**Visuals**

Line chart with markers, titled 'Drug dose adjusted in course', inside a thin grey rectangular border. Y axis labelled 'Parameter', range 0.0 to 3.0 with ticks every 0.5 (values about, unitless). X axis labelled 'Time, hours', range -2.0 to 7.0 with ticks every 1.0. Series 1, 'First course, drug dose corrected in course': navy #2E3A6B line with diamond markers; values about 0 at -1.0 to 0.0, rising to about 1.05 near 0.6 and about 1.05 near 1.3, falling to about 0 at 2.0, then about 0 at 2.5, 3.0, 3.5, 4.0, 5.0 and 6.0. Series 2, 'Drug level': magenta #E0007F line with square markers; about 0.0 at -1.0 and 0.0, about 0.7 at 0.5, about 1.5 at 1.0, about 2.5 at 1.5 (peak), about 1.5 at 2.0, about 1.0 at 2.5, about 0.75 at 3.0, about 0.5 at 3.5, about 0.4 at 4.0, about 0.35 at 5.0, about 0.25 at 6.0. Series 3, 'Drug level target': red #FF0000 line with triangle markers, flat at about 1.0 from 0.5 to 3.0 (triangles at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0). Legend box at upper right inside the plot area, white fill with grey border, listing the three series with their marker symbols. No highlighted points beyond the peak. Decorative binary-code banners (blue gradient fading to white) at top right and bottom left, not charts.

**Design**

Background: White #FFFFFF with blue binary-code banners at top right and bottom left. White background with blue binary-code graphic banners at top right (blue #3A7FC1 fading to white) and bottom left. Title in bold Arial/Helvetica sans-serif, colour blue #1B6CA8, about 5.3% of slide height. Body text in regular Arial/Helvetica sans-serif, dark grey #333333, about 3.6% of slide height, line spacing about 3.9%. Chart text in Arial, black #000000 axis labels, bold chart title and axis titles. Chart border thin grey #808080, no shadow. Footer and page number in grey #6E6E6E Arial, footer bold about 1.7%, page number regular about 3.0%. Logo in green #3E9A5A serif display type with trademark mark.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- illustration at x 27, y 5.8, w 68.5, h 13.6 [#3A7FC1]: Blue binary-code banner fading to white, top right corner (Background graphic behind the title area, soft fading left edge, no border; overlaps nothing important.)
- illustration at x 4.5, y 82, w 58, h 12 [#2F6FB5]: Blue binary-code banner fading to white, bottom left corner (Background graphic at bottom left behind the footer area, fading to white toward the right, no border.)
- logo at x 6.8, y 7.6, w 19.8, h 5.6 [#3E9A5A; left aligned]: Theranos logo (green serif wordmark with caduceus-style T and TM mark) (Green outlined serif wordmark with a darker green outline, TM superscript at upper right.)
- title at x 7.8, y 16.2, w 36.5, h 4.6 [Arial, bold; font size 5.3% of slide height; #1B6CA8; left aligned]: Dose Customization (Single line, no italics, no caps, normal letter-spacing.)
- chart at x 17.9, y 22.1, w 57.5, h 45.5 [#FFFFFF]: Line and marker chart titled 'Drug dose adjusted in course' with Parameter and Time, hours axes and three series with a legend (Chart area white with thin grey #808080 border; plot area grey border; navy #2E3A6B diamonds, magenta #E0007F squares, red #FF0000 triangles; legend box at upper right of plot with grey border; chart title bold Arial about 1.9% of height; axis labels Arial about 1.8%.)
- body at x 13.1, y 69.6, w 70.4, h 11.3 [Arial, regular; font size 3.6% of slide height; #333333; left aligned]: Same patient but in the first course rapid (within one hour) / feedback from Theranos monitor leads to a decision to stop the / infusion. Drug level drops from toxic to target. (Three lines, line spacing about 3.9% of slide height, no bullets.)
- footer at x 71.7, y 88.8, w 14, h 1.8 [Arial, bold; font size 1.7% of slide height; #6E6E6E; right aligned]: Confidential & Proprietary (Single line, sits at the baseline of the page number.)
- page number at x 90.2, y 89, w 2.3, h 2.1 [Arial, regular; font size 3% of slide height; #6E6E6E; right aligned]: 12 (Bottom right corner of the slide.)

### Slide 13

**Review notes**

- Review: Several pages have fit and legibility defects: the caption on slide 22 collides with the footer band, slide 23 text overlaps the footer, the chart on slide 13 has overprinted axis labels and unreadable noise, and slide 6 pairs unlabeled drawings with a stock server photo and no explanation.
- Suggested repair: Fix the text colliding with the footer band on slides 22 and 23, enlarge or split the dense management and investor lists on slides 4 and 21, and cut the chart on slide 13 down to a readable message.

**Text**

Theranos
Real-time PK/PD Monitoring
Scenario: Drug effective; Toxicity observed; Dosage reduced; Toxicity reduced to acceptable level
1.4
1.2
1
0.8
0.6
0.4
0.2
0
-10.0
0.0
10.0
20.0
30.0
40.0
50.0
Parameter Value
Time, days
Drug Dose
Drug Level
Effect marker
Toxicity marker
Tox. Alert Level
Confidential & Proprietary
13

**Layout**

Full-width title sits top-left below the logo, with the chart box centred horizontally below it, spanning about 17% to 83% of the width. The logo is at top-left, a binary-code graphic fills the top-right corner, and the footer 'Confidential & Proprietary' and page number '13' sit at bottom-right, with a binary-code graphic at bottom-left.

**Visuals**

Line chart with title 'Scenario: Drug effective; Toxicity observed; Dosage reduced; Toxicity reduced to acceptable level' (bold, two lines, centred above plot). X-axis 'Time, days' from -10.0 to 50.0 with ticks every 10 (labels -10.0, 0.0, 10.0, 20.0, 30.0, 40.0, 50.0). Y-axis 'Parameter Value' from 0 to 1.4 with ticks every 0.2 (0, 0.2, 0.4, 0.6, 0.8, 1, 1.2, 1.4). Series: Drug Dose (navy #1F1F5C line with diamond markers) about 1 from day 0 to 7, about 0 at days 7 to 8, about 1 from day 8 to 11, then about 0.5 from day 12 to 50. Drug Level (magenta #E0007F line with square markers) peaks about 1.3 near days 2 and 3, about 1.2 near day 10.5, then oscillates between about 0.3 and 0.9 and settles between about 0.3 and 0.6 after day 13. Effect marker (green #00A651 line with triangle markers) starts about 1 at day 0, falls to about 0 near day 7, peaks about 0.25 near day 4.5, then settles between about 0.1 and 0.15 after day 15. Toxicity marker (light blue #00B0F0 line with x markers) peaks about 1.3 at day 10.5, then oscillates between about 0.1 and 0.5 after day 15. Tox. Alert Level is a horizontal red #FF0000 line at 0.4 spanning day 0 to 50. Legend box at upper right of plot lists the five series in order: Drug Dose, Drug Level, Effect marker, Toxicity marker, Tox. Alert Level. No highlighted points.

**Design**

Background: White #FFFFFF with blue binary-code graphic fading to white at top-right and bottom-left. White background with blue binary-code graphics at top-right and bottom-left. Title in blue #0F6A9E sans-serif (Arial-like) regular weight, about 5.5% of slide height. Chart title and axis labels in bold black #000000 sans-serif (Arial-like). Tick labels in dark grey #333333 sans-serif. Footer and page number in grey #6D6E71 sans-serif, bold for footer. Logo is green #3A9A5B serif-style wordmark. Chart box has thin grey #7F7F7F border with no fill.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- illustration at x 25, y 5.5, w 71, h 14: Blue binary-code (0s and 1s) gradient graphic fading to white, top-right corner (Blue #2F7FC1 to light blue #9FC9E8 gradient, tapered wedge shape, fades left into white)
- logo at x 6.8, y 7.8, w 19.8, h 5.2 [#3A9A5B]: Theranos logo wordmark with TM (Green serif wordmark with a caduceus-like staff on the T, TM superscript at top-right)
- title at x 7.8, y 17, w 55, h 6.5 [Arial-like sans-serif, regular; font size 5.5% of slide height; #0F6A9E; left aligned]: Real-time PK/PD Monitoring
- shape at x 17, y 23.2, w 66, h 60.6 [#FFFFFF]: Chart frame box (Thin grey #7F7F7F border, no fill, square corners)
- chart at x 21.6, y 31.5, w 57, h 51 [#FFFFFF]: Line chart of PK/PD scenario with four series and one alert line, legend at upper right of plot (Plot area bordered by thin grey lines; axes in dark grey; gridlines none)
- caption at x 24.5, y 25, w 51, h 6.5 [Arial-like sans-serif, bold; font size 2.2% of slide height; #000000; center aligned]: Scenario: Drug effective; Toxicity observed; Dosage reduced; Toxicity / reduced to acceptable level (Two centred lines, line spacing about 1.2)
- shape at x 59, y 33.7, w 22, h 16 [#FFFFFF]: Legend box with five entries (Thin grey border, no fill; entries show line segment with marker: navy diamond Drug Dose, magenta square Drug Level, green triangle Effect marker, cyan x Toxicity marker, red line Tox. Alert Level)
- body at x 17.5, y 47, w 2.5, h 17 [Arial-like sans-serif, bold; font size 2.2% of slide height; #000000; center aligned]: Parameter Value (Rotated 270 degrees, reads bottom to top)
- body at x 46, y 81, w 9, h 3 [Arial-like sans-serif, bold; font size 2.2% of slide height; #000000; center aligned]: Time, days
- footer at x 71.5, y 88.5, w 14.5, h 2.5 [Arial-like sans-serif, bold; font size 2% of slide height; #6D6E71; right aligned]: Confidential & Proprietary
- page number at x 90, y 88.2, w 3.5, h 3.5 [Arial-like sans-serif, regular; font size 3.6% of slide height; #6D6E71; right aligned]: 13
- illustration at x 4.5, y 84, w 59, h 10.5: Blue binary-code graphic fading to white, bottom-left corner (Blue #2F7FC1 to light blue gradient, fades right into white)

### Slide 14

**Text**

Theranos™ / Total Available Market: / Phase IV Clinical Trials / Phase IV Clinical Market = $39 Billion per year / Number of ongoing trials per year = 600 to 800 / Average Theranos Revenue per trial = $50M / $7,500 “Information Fee” per patient for every four months / Average: 2,000 to 10,000 patients per trial / Confidential & Proprietary / 14

**Layout**

Single content slide with a centred bold title in the upper third and a left-aligned bulleted list below it, indented to about 13% of slide width. The Theranos logo sits top-left, a binary-code banner runs across the top right, a matching banner sits bottom-left, and the footer 'Confidential & Proprietary' and page number '14' sit bottom-right on one baseline. Margins are about 5% on the left and 10% on the right.

**Visuals**

Two decorative binary-code banners (blue digit strips fading to white) and one green Theranos wordmark with a trademark mark. No charts, tables or photographs. The top banner is a wide gradient strip with blue binary digits (0s and 1s) fading to white toward the left and bottom. The bottom-left banner is a smaller strip of pale blue binary digits fading to white toward the top-right. The Theranos wordmark is green serif-style lettering with a dark green outline and a small TM mark at upper right.

**Design**

Background: White #FFFFFF with blue binary-code gradient banners at top right and bottom left. White background with blue binary-code banners at top right and bottom left. Title text is bold sans-serif (Arial/Helvetica Bold) in blue #0A6BA8, about 5% of slide height, centred. Body bullets are regular sans-serif (Arial/Helvetica) in dark grey #333333, about 3.4% of slide height. Bullet markers are small dark grey arrowheads (Wingdings-style '➢') in #333333. The footer is bold sans-serif grey #777777 at about 1.6% of slide height. The page number is regular sans-serif grey #808080 at about 3% of slide height. The logo is green #3E9E5A with darker green outline. No shadows, corner radii or boxes; the banners are soft gradients.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- illustration at x 27, y 5.8, w 68.5, h 13.6 [#3A7FD0]: Top binary-code banner: wide gradient strip of blue binary digits fading to white toward the left and bottom (Back layer. Gradient fades from solid blue at the right edge to white at the left; soft edges, no border, no shadow.)
- illustration at x 4.5, y 81, w 58, h 13.3 [#8DB8E6]: Bottom-left binary-code banner: pale blue strip of binary digits fading to white toward the top right (Back layer. Gradient fades to white at the top and right; soft edges, no border, no shadow.)
- logo at x 6.8, y 7.8, w 19.8, h 5.2 [#3E9E5A]: Theranos wordmark with TM mark (Green serif-style lettering with darker green outline; small 'TM' superscript at upper right of the wordmark.)
- title at x 29.4, y 24, w 41.3, h 10.4 [Arial/Helvetica, bold, sans-serif, mixed case; font size 5% of slide height; #0A6BA8; center aligned]: Total Available Market: / Phase IV Clinical Trials (Two lines, centred; line spacing about 1.2.)
- bullet list at x 10.5, y 39.5, w 68, h 39 [Arial/Helvetica, regular, sans-serif, mixed case; font size 3.4% of slide height; #333333; left aligned]: Phase IV Clinical Market = $39 Billion per year / Number of ongoing trials per year = 600 to 800 / Average Theranos Revenue per trial = $50M / $7,500 “Information Fee” per patient for every four months / Average: 2,000 to 10,000 patients per trial (Five bullets with arrowhead markers (➢) in #333333 at the left of each line, text starting about 13% from left. Items spaced about 8.5% of slide height apart, with a blank line between each item.)
- footer at x 71.7, y 89, w 14, h 1.8 [Arial/Helvetica, bold, sans-serif, mixed case; font size 1.6% of slide height; #777777; left aligned]: Confidential & Proprietary
- page number at x 90.3, y 88.5, w 2.2, h 2.5 [Arial/Helvetica, regular, sans-serif; font size 3% of slide height; #808080; right aligned]: 14

### Slide 15

**Text**

Theranos
Total Available Market:
Pharmaceutical preclinical market
Pre-clinical Market = $10 billion per year
$5M annual revenue per research group
133 groups per pharmaceutical company
15 companies of this size
Note: These numbers exclude sales to one of the largest preclinical market segments:  academic institutions.
Confidential & Proprietary
15

**Layout**

Single-column content slide with the title centred at the top beneath the logo and binary-code banner. Bulleted body text is left-aligned at about 11% from the left edge, with a note paragraph below. Footer confidentiality mark sits right of centre near the bottom, with the slide number at the bottom right; a binary-code banner runs along the top right and bottom left.

**Visuals**

A green serif 'Theranos' wordmark with trademark symbol at top left, on a white ground. A blue gradient binary-code (0s and 1s) banner runs across the top from about 27% to the right edge, fading to white toward the left. A second, smaller blue binary-code banner sits bottom left, fading to white toward the right. No charts, photographs or diagrams.

**Design**

Background: White (#FFFFFF) with blue binary-code gradient banners at top right and bottom left. White background with blue binary-code gradient banners at top right and bottom left. Title text is bold sans-serif (Arial/Helvetica-style) in a medium blue (#1A6EA8), approximately 4.5% of slide height per line. Body text is regular Arial/Helvetica-style sans-serif in dark charcoal (#333333); first-level bullets about 4.2% of slide height, second-level bullets about 3.2%. Bullets are blue chevron arrows (#1A6EA8). Note paragraph is about 4.2% in charcoal. Footer 'Confidential & Proprietary' is bold grey (#666666) sans-serif about 1.5%; slide number is regular grey sans-serif about 3.5%. Wordmark is green (#2E8B57) serif. No shadows, no rounded corners, no visible shape outlines.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- logo at x 7, y 6, w 19, h 7 [serif, bold; #2E8B57; left aligned]: Theranos wordmark with trademark symbol (TM) (Green serif wordmark with a caduceus-like emblem in the T; outlined letters; trademark symbol at upper right.)
- shape at x 27, y 5, w 73, h 13 [#4A86C8]: Top-right binary-code gradient banner (Blue binary-code (0s and 1s) texture fading to white toward the left edge; no outline.)
- shape at x 4, y 81, w 58, h 18 [#3F7FC4]: Bottom-left binary-code gradient banner (Blue binary-code texture fading to white toward the upper right; no outline.)
- title at x 19, y 18, w 62, h 12 [Arial/Helvetica sans-serif, bold, normal case; font size 4.5% of slide height; #1A6EA8; center aligned]: Total Available Market: / Pharmaceutical preclinical market (Two lines; line spacing about 1.1.)
- bullet list at x 11, y 38, w 60, h 21 [Arial/Helvetica sans-serif, regular, normal case; font size 4.2% of slide height; #333333; left aligned]: Pre-clinical Market = $10 billion per year / $5M annual revenue per research group / 133 groups per pharmaceutical company / 15 companies of this size (First-level bullet 'Pre-clinical Market = $10 billion per year' at about 4.2%; three second-level bullets indented at about 15% from left edge at about 3.2%; blue chevron bullet markers (#1A6EA8).)
- body at x 11, y 62, w 70, h 14 [Arial/Helvetica sans-serif, regular, normal case; font size 4.2% of slide height; #333333; left aligned]: Note: These numbers exclude sales to one of the largest preclinical market segments: academic institutions. (Three lines with hanging indent; second and third lines aligned with text after 'Note:' start.)
- footer at x 71, y 88, w 18, h 2 [Arial/Helvetica sans-serif, bold, normal case; font size 1.5% of slide height; #666666; right aligned]: Confidential & Proprietary
- page number at x 90, y 88, w 4, h 3 [Arial/Helvetica sans-serif, regular; font size 3.5% of slide height; #666666; right aligned]: 15

### Slide 16

**Review notes**

- Review: But the deck runs mostly as unvarying bullet lists with tiny type on slides 4 and 21, and the route is muddled: management comes at slide 4 before the product is shown, the value proposition appears twice (slides 9 and 16), and the offering and investor slides sit before a technology slide at the end.
- What would change the score: I would reorder to problem, solution, product, evidence, market, team, offering, and turn the bullet-only slides 3, 9, 16, 17 and 18 into fewer, headline-led pages with a clear point each.

**Text**

Theranos
Theranos Value Proposition
Revenue:
Information fee includes use of
Readers
Cartridges
ABCS informatics, patient diary and data integration service
70% margins
Requisite solution for improving labels or preempting liabilities
Cost to pharmaceutical companies is 20-30% less than current costs of equivalent testing through clinicians office
Confidential & Proprietary
16

**Layout**

Single left-aligned text column below a logo at top left and a title beneath it, with the body starting at about 8.5% from the left edge. Binary-code banners sweep across the top-right and bottom-left corners. The footer 'Confidential & Proprietary' sits bottom right with the slide number 16 to its right at the same baseline, and there is no other footer.

**Visuals**

Two decorative illustrations: a blue binary-code (0s and 1s) banner in the top right that tapers and fades to white toward the left and bottom, and a second, fainter binary-code banner in the bottom left that fades to white toward the right. Both are full-width bleed bands with soft gradient edges. The Theranos logo is a green serif wordmark with a caduceus-like staff over the T and a trademark TM mark, at top left. No charts, tables or photographs.

**Design**

Background: Solid white #FFFFFF with binary-code blue gradient banners at top right and bottom left. Plain white background with blue binary-code gradient banners in the corners. Title is a regular-weight sans-serif (Arial/Helvetica style) in blue, about 5% of slide height. Body text is regular sans-serif (Arial/Helvetica style) in dark grey, about 3.5% of slide height for level 1 and level 2, with the final bullet about 4.3%. Level 1 bullets are blue diamond glyphs (❖) and level 2 bullets are small blue square glyphs. Footer is bold sans-serif, about 2% of slide height, mid grey. No shadows, borders or corner radii on text elements.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- illustration at x 27, y 6, w 69, h 14 [#3E7FCB]: Top-right binary-code banner: blue 0s and 1s tapering from full-width at right to transparent at left and bottom (Gradient from medium blue #3E7FCB to white; soft faded left and lower edges; sits behind the title area; no border)
- illustration at x 4.5, y 81.6, w 58, h 12.6 [#8FB4E3]: Bottom-left binary-code banner: faint blue 0s and 1s fading to white toward the right (Gradient from light blue #8FB4E3 to white; soft upper and right edges; no border)
- logo at x 7, y 8, w 20, h 5.2 [#3A9A5B]: Theranos logo wordmark with TM mark (Green (#3A9A5B) serif wordmark with a dark green outline; trademark TM superscript at upper right)
- title at x 8, y 18, w 47, h 5 [Arial/Helvetica style sans-serif, regular weight, no italics, no capitals beyond initial letters, normal letter-spacing; font size 5% of slide height; #1A74B0; left aligned]: Theranos Value Proposition
- body at x 8.5, y 27.5, w 80, h 42 [Arial/Helvetica style sans-serif, regular weight, normal case, normal letter-spacing; font size 3.5% of slide height; #333333; left aligned]: Revenue: / Information fee includes use of / Readers / Cartridges / ABCS informatics, patient diary and data integration service / 70% margins / Requisite solution for improving labels or preempting liabilities / Cost to pharmaceutical companies is 20-30% less than current costs of equivalent testing through clinicians office (Line spacing about 1.4. 'Revenue:' has no bullet. Level 1 items use blue diamond bullets (❖) at about 9% from left. Level 2 items 'Readers', 'Cartridges' and 'ABCS informatics...' are indented with small blue square bullets (▪) at about 12.5% from left. The final bullet 'Cost to pharmaceutical companies...' is larger, about 4.3% em, and wraps onto a second line aligned with its text.)
- footer at x 71.7, y 88.8, w 14, h 3 [Arial/Helvetica style sans-serif, bold weight, normal case, normal letter-spacing; font size 2% of slide height; #6B6B6B; right aligned]: Confidential & Proprietary
- page number at x 90.3, y 89, w 4, h 3.5 [Arial/Helvetica style sans-serif, regular weight, normal case, normal letter-spacing; font size 2.8% of slide height; #6E6E6E; right aligned]: 16

### Slide 17

**Review notes**

- What would change the score: I would reorder to problem, solution, product, evidence, market, team, offering, and turn the bullet-only slides 3, 9, 16, 17 and 18 into fewer, headline-led pages with a clear point each.

**Text**

Theranos / ™ / Pains In The Existing Marketplace / Adverse Drug Reactions reduce sales and keep some drugs off the market / Pharmacogenomic tests (diagnostics) do not eliminate adverse drug reactions / And screen some patients who could safely benefit from a drug / No mechanism to measure the effect of environmental factors on drug efficacy / No continuous monitoring to determine the correct dosage / Current testing procedures too expensive or impossible for some drugs / Confidential & Proprietary / 17

**Layout**

Single-column bulleted slide on a white field with the title left-aligned near the top under the logo, bullets in a left-aligned column starting at about 9% from the left edge, and a footer band at the bottom right with confidentiality mark and slide number. A blue binary-code gradient banner runs across the top right and a fainter one along the bottom left.

**Visuals**

Top-right banner: a horizontal swoosh of blue binary digits (0s and 1s) fading from saturated blue at the right edge to white toward the left, spanning roughly x 27% to 100% and y 4% to 18%. Bottom-left banner: a pale blue binary-digit band fading from white at the top to light blue at the bottom, spanning roughly x 4% to 63% and y 75% to 95%. Logo: the Theranos wordmark in green serif lettering with a small caduceus-style emblem in the T, with a TM mark at upper right, at top left. No photographs or charts.

**Design**

Background: Plain white (#FFFFFF) with blue binary-code gradient banners at top right and bottom left. White background (#FFFFFF). Title in bold sans-serif (Arial Bold style), blue #0067A6 (approximately), about 4.5% of slide height. Body text in regular sans-serif (Arial style), dark grey #3A3A3A, about 3.2% of slide height for level-one bullets and about 2.6% for the indented sub-bullet. Bullets are blue arrowhead glyphs (Wingdings-style chevron arrow) in #1F6FB5 for the first and sub-bullets, and smaller blue arrows for the later level-one bullets. Line spacing is about 1.1 with generous gaps between bullets. Footer text 'Confidential & Proprietary' is bold grey sans-serif, about 1.4% of slide height, and the slide number '17' is regular grey sans-serif about 2.6%. No shapes, borders or shadows.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- illustration at x 27, y 4, w 73, h 14 [#3F7FD0]: Top-right binary-code gradient banner, blue digits fading to white toward the left (Horizontal swoosh, saturated blue at right edge fading to white at left, decorative background behind title area, no border)
- logo at x 7, y 6, w 27, h 7 [Serif wordmark (custom), bold; #2E8B57; left aligned]: Theranos logo: green serif wordmark 'Theranos' with caduceus emblem in the T and TM mark (Green outlined lettering with white inner fill, TM superscript at upper right)
- title at x 8, y 16, w 68, h 7 [Arial, bold, regular case, no letter-spacing; font size 4.5% of slide height; #0067A6; left aligned]: Pains In The Existing Marketplace (Single line, baseline near 21% of height)
- bullet list at x 8, y 28, w 83, h 47 [Arial, regular, sans-serif; font size 3.2% of slide height; #3A3A3A; left aligned]: Adverse Drug Reactions reduce sales and keep some drugs off / the market / Pharmacogenomic tests (diagnostics) do not eliminate adverse / drug reactions / And screen some patients who could safely benefit from a drug / No mechanism to measure the effect of environmental factors on / drug efficacy / No continuous monitoring to determine the correct dosage / Current testing procedures too expensive or impossible for some / drugs (Blue chevron arrow bullets (#1F6FB5); level-one bullets with hanging indent, one sub-bullet at level two with smaller arrow and smaller text at about 2.6% of slide height; wrapped lines aligned under text start; line spacing about 1.1)
- banner at x 4, y 75, w 59, h 20 [#BFD6F0]: Bottom-left binary-code gradient band, pale blue digits fading to white at top (Fades from white at top to light blue at bottom edge, sits behind footer area on left side)
- footer at x 71, y 88, w 15, h 3 [Arial, bold, regular case; font size 1.4% of slide height; #6B6B6B; right aligned]: Confidential & Proprietary (Small grey text, right-aligned, sits left of slide number)
- page number at x 90, y 88, w 5, h 4 [Arial, regular; font size 2.6% of slide height; #6B6B6B; right aligned]: 17 (Right of footer text, bottom right corner margin about 4%)

### Slide 18

**Review notes**

- What would change the score: I would reorder to problem, solution, product, evidence, market, team, offering, and turn the bullet-only slides 3, 9, 16, 17 and 18 into fewer, headline-led pages with a clear point each.

**Text**

Theranos Solution
Monitoring can take place anywhere and can be done by anyone
Monitoring can be as frequent as needed with little increase in cost
Results compare to / beat those obtained by a blood lab
Results are available in minutes
Warning to doctor can be sent within minutes of a test
Effectiveness of dose can be monitored in real time
Drug-drug combinations can be monitored to improve the label
Drugs can be prescribed with monitoring devices to prevent ADRs
Instant analysis and availability of related data improve speed and effectiveness of trials
Consumer WWW increases value of therapy: Informs patients, drives compliance and increases patient adherence to given drug
Confidential & Proprietary
18

**Layout**

Single-column slide with the title at upper left and a bulleted body list below it, occupying roughly the left 85% of the width. A blue binary-code gradient band runs across the top right and a second band sits across the bottom left, with the Theranos logo at top left and the footer confidentiality mark and page number at bottom right. Left margin is about 8% of width and text is left-aligned.

**Visuals**

Decorative background bands only, no photographs or charts. Top-right band: a horizontal strip of blue binary digits (0s and 1s) fading from saturated medium blue #3F7FC4 at its right edge to white at its left edge, tapering diagonally, spanning roughly the top 19% of the slide. Bottom-left band: a faded light blue binary-digit strip fading to white toward the right, spanning about y 81% to 95% and x 4% to 62%, with a soft gradient edge. Logo: Theranos wordmark in green #3A9A5B serif-style letters with a small caduceus-like emblem in the T, and a small TM mark at upper right of the wordmark. Bullet glyphs are small blue arrowhead symbols (Wingdings-style) in #1F6FA8.

**Design**

Background: White #FFFFFF with blue binary-code gradient bands at the top right and bottom left. White background with blue binary-code gradient bands at top right and bottom left. Title in bold sans-serif (Arial/Helvetica Bold) in blue #0E6BA8, about 4.5% of slide height. Body text in regular Arial/Helvetica in dark grey #333333, about 3.2% of slide height, with the bullets in blue #1F6FA8. Footer text in bold sans-serif grey #6D6E71, about 1.6% height. Page number in regular sans-serif grey #6D6E71, about 2.8% height. Line shapes are none; no shadows, no rounded corners, no gradients other than the binary band fades.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 27, y 6, w 69, h 14 [#3F7FC4]: Top-right binary-code gradient band (Horizontal strip of blue 0/1 digits, fading to white on its left edge; upper and lower edges taper; sits behind the title area but does not overlap text.)
- shape at x 4.5, y 81, w 58, h 14 [#B8CDE6]: Bottom-left binary-code gradient band (Faded light blue 0/1 digits fading to white toward the right, soft edges, no overlap with body text.)
- logo at x 7, y 7.5, w 20, h 6.5 [Serif display wordmark; #3A9A5B; left aligned]: Theranos logo with TM mark (Green wordmark with caduceus emblem in the T and small TM superscript at top right.)
- title at x 8, y 17, w 35, h 6 [Arial/Helvetica, bold; font size 4.5% of slide height; #0E6BA8; left aligned]: Theranos Solution (Sentence-case title, no italics, no letter-spacing.)
- bullet list at x 8.5, y 21.5, w 84, h 38 [Arial/Helvetica, regular; font size 3.2% of slide height; #333333; left aligned]: Monitoring can take place anywhere and can be done by anyone / Monitoring can be as frequent as needed with little increase in cost / Results compare to / beat those obtained by a blood lab / Results are available in minutes / Warning to doctor can be sent within minutes of a test / Effectiveness of dose can be monitored in real time / Drug-drug combinations can be monitored to improve the label / Drugs can be prescribed with monitoring devices to prevent ADRs / Instant analysis and availability of related data improve speed and / effectiveness of trials / Consumer WWW increases value of therapy: Informs patients, drives / compliance and increases patient adherence to given drug (Eleven bullets with blue arrowhead glyphs in #1F6FA8 at left; line spacing about 1.4; the last two bullets wrap to a second line; roughly 0.7% of height between bullets.)
- footer at x 71, y 88.5, w 14, h 2.5 [Arial/Helvetica, bold; font size 1.6% of slide height; #6D6E71; right aligned]: Confidential & Proprietary (Sits at the same baseline as the page number.)
- page number at x 90, y 88, w 4, h 3.5 [Arial/Helvetica, regular; font size 2.8% of slide height; #6D6E71; right aligned]: 18 (Slide number at bottom right.)

### Slide 19

**Text**

Theranos / Drivers for Success / First mover advantage / Combination of several different technologies makes reproducing the solution difficult / Innovation Pipeline: Next generation systems / Strong Customer Base / Speed to Market and Focus on Quality / Patents / Management and Culture / Confidential & Proprietary / 19

**Layout**

Single-column layout on a white slide with a blue binary-code swoosh across the top right and a fainter one across the bottom left. The Theranos logo sits top left, the title sits left-aligned below it, and the bullet list is left-aligned in one column below the title. The footer 'Confidential & Proprietary' sits bottom right, with the slide number to its right at the bottom edge. Margins are about 7 to 8 percent on the left and about 4 to 5 percent on the right.

**Visuals**

Two decorative illustrations, both made of blue binary digits (0s and 1s) on a fading white field. The top-right illustration is a horizontal band of blue binary text, darkest blue at its right edge and fading to white toward the left and bottom, with a tapered lower edge. The bottom-left illustration is a band of pale blue binary text that fades to white toward the top and right. No photographs, charts, tables, or diagrams. The only logo is the green Theranos wordmark with a trademark mark at its top right.

**Design**

Background: White #FFFFFF with blue binary-code swoosh illustrations at top right and bottom left. White background with blue binary-code decorative bands. Title text is blue #1F6FB2 in a regular-weight Arial-like sans-serif, about 4.5% of slide height. Body bullets are dark grey #333333 in a regular-weight Arial-like sans-serif, about 3.6% of slide height, with generous line spacing of about 5.5% of slide height between items. Bullet markers are small blue #1F5FA8 arrowheads. Footer text is bold grey #6D6E71 in Arial-like sans-serif at about 1.6% of slide height. Slide number is regular grey #666666 in Arial-like sans-serif at about 2.7% of slide height. Logo is green #3A9A4A with a darker green outline. No shapes, lines, or shadows.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- illustration at x 27, y 5.8, w 68.5, h 13.6 [#3F7FCB]: Top-right blue binary-code swoosh band, darkest blue at right edge fading to white toward left and bottom (Full-width band cropped at the right slide edge, soft fading gradient to white on its left and lower edges, no border, no overlay)
- illustration at x 4.5, y 80.9, w 58, h 13.3 [#A9C8E8]: Bottom-left pale blue binary-code band fading to white toward top and right (Soft gradient fade to white on top and right edges, no border, no overlay)
- logo at x 6.75, y 7.8, w 19.25, h 5.2 [Serif display wordmark, bold; #3A9A4A; left aligned]: Theranos wordmark logo in green serif letters with a trademark symbol at top right (Green fill #3A9A4A with darker green outline, trademark TM mark at top right corner)
- title at x 7.85, y 17.8, w 26.2, h 3.6 [Arial-like sans-serif, regular weight; font size 4.5% of slide height; #1F6FB2; left aligned]: Drivers for Success (Single line)
- bullet list at x 10, y 26, w 75, h 43 [Arial-like sans-serif, regular weight; font size 3.6% of slide height; #333333; left aligned]: First mover advantage / Combination of several different technologies makes reproducing the solution difficult / Innovation Pipeline: Next generation systems / Strong Customer Base / Speed to Market and Focus on Quality / Patents / Management and Culture (Seven items, each preceded by a small blue #1F5FA8 arrowhead bullet, text indented to about 12.35 percent of slide width, line spacing about 5.5 percent of slide height between items, the second item wraps onto a second line)
- footer at x 71.7, y 88.8, w 14.2, h 2.3 [Arial-like sans-serif, bold weight; font size 1.6% of slide height; #6D6E71; right aligned]: Confidential & Proprietary (Small grey footer text)
- page number at x 90.25, y 88.9, w 2.2, h 2.3 [Arial-like sans-serif, regular weight; font size 2.7% of slide height; #666666; right aligned]: 19 (Slide number at bottom right)

### Slide 20

**Text**

Theranos™ / Offering / Objective: Pre-IPO transaction to facilitate rapid scaling of Theranos production and manufacturing infrastructure and add to Theranos business development and sales force. / CFP / Offering: $30M / Existing Investors: $15-20M / New Investors: $10-15M / Confidential & Proprietary / 20

**Layout**

Single-column bulleted body below a title, with the Theranos logo in the top-left corner and a binary-code graphic band across the top-right and bottom-left. The title sits at left margin under the logo; body text is left-aligned with two-level bullets indented from the left margin. Footer 'Confidential & Proprietary' sits right of centre at the bottom-right with the slide number 20 at the far right.

**Visuals**

Decorative graphic: a blue gradient band of binary digits (1s and 0s) fading to white, running from the top-right corner leftward and tapering to the left, and a second smaller band of binary digits at the bottom-left fading to white toward the right. No photographs, charts, or tables. Logo: green 'Theranos' wordmark with a stylised caduceus-like figure replacing the 'T', outlined in lighter green, with a small TM mark at upper right.

**Design**

Background: White #FFFFFF with blue binary-code gradient bands at top-right and bottom-left. White background with blue binary-code gradient bands at top-right and bottom-left. Title in bold sans-serif (Arial Bold-like), blue #0070A0-ish, roughly 5% of slide height. Body text in regular sans-serif (Arial-like) dark grey #333333, first-level about 4.2% of slide height, second-level about 3.4%. Bullets: first level blue diamond-shaped ❖ markers in blue #0070A0; second level small blue square markers #1F6FB5. Footer text bold sans-serif grey #666666 about 1.4% of height; page number regular sans-serif grey #666666 about 2.6% of height. Logo green #3A9A5B with lighter green outline. No shadows or rounded corners.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- logo at x 6.5, y 6, w 20, h 7 [#3A9A5B; left aligned]: Theranos wordmark logo with TM mark (Green serif-style wordmark with caduceus-like T, lighter green outline, TM superscript at upper right.)
- shape at x 27, y 4, w 73, h 14 [#4A7FD0]: Top-right binary-code gradient band (Blue binary digit field fading to white toward the left and bottom, tapering diagonally; no border.)
- shape at x 4.5, y 72, w 62, h 21 [#2A6FB8]: Bottom-left binary-code gradient band (Blue binary digit field fading to white toward the right and top; no border.)
- title at x 7.5, y 17, w 17, h 6 [Arial, bold, normal case; font size 5% of slide height; #0070A0; left aligned]: Offering (No letter-spacing adjustment.)
- bullet list at x 10.5, y 24, w 82, h 20 [Arial, regular; font size 4.2% of slide height; #333333; left aligned]: Objective: Pre-IPO transaction to facilitate rapid scaling of / Theranos production and manufacturing infrastructure and / add to Theranos business development and sales force. / CFP (First-level blue diamond bullet ❖ #0070A0; second-level 'CFP' with small blue square bullet; line spacing about 1.2; second-level text about 3.4% of slide height.)
- bullet list at x 10.5, y 49, w 52, h 17 [Arial, regular; font size 4.2% of slide height; #333333; left aligned]: Offering: $30M / Existing Investors: $15-20M / New Investors: $10-15M (First-level blue diamond bullet ❖ #0070A0 for 'Offering: $30M'; two second-level items with small blue square bullets; line spacing about 1.2.)
- footer at x 71.5, y 88.5, w 16.5, h 2 [Arial, bold, normal case; font size 1.5% of slide height; #666666; right aligned]: Confidential & Proprietary (Small bold grey text.)
- page number at x 90, y 88, w 4.5, h 3.5 [Arial, regular; font size 2.6% of slide height; #666666; right aligned]: 20 (Slide number in regular grey.)

### Slide 21

**Review notes**

- Review: But the deck runs mostly as unvarying bullet lists with tiny type on slides 4 and 21, and the route is muddled: management comes at slide 4 before the product is shown, the value proposition appears twice (slides 9 and 16), and the offering and investor slides sit before a technology slide at the end.
- Suggested repair: Fix the text colliding with the footer band on slides 22 and 23, enlarge or split the dense management and investor lists on slides 4 and 21, and cut the chart on slide 13 down to a readable message.

**Text**

Theranos / Existing Investors / Lead investor profiles: / Series A / Chang, Esoom Taipei: Multi-billion dollar distribution group; leading distributors of high / technology devices in Asia with headquarters in China and in Taiwan. / Continental Properties Company: Fund lead by John Schweitzer and Stephen Feinberg, / director of MD Anderson, leading center in innovative cancer treatment, cutting-edge / research and clinical trials. / Draper Fisher Jurvetson: Draper Fisher Jurvetson is a global network of affiliated venture / funds with over $3 billion in capital commitments and offices in the major technology centers / around the world. / Jupiter Partners: Fund lead by John Bryan, limited partner in numerous venture capital and / private equity funds and leading investor in companies ranging from Amgen to Hewlett / Packard. / Palmieri Trust: Fund lead by Victor Palmieri, business takeover financier; director of / numerous high growth companies including Phillips Petroleum, the Pennsylvania Company, / Arvida Corporation, Outlet Communications, the William Carter Company, Broadcasting / Partners, and Mullin Consulting and a Trustee of The Rockefeller Foundation. / Series B / Donald L Lucas fund: Premier Silicon Valley venture capital veteran (note biography in board / profile document) / ATA Ventures (Early Stage Venture Capital) / Larry Ellison, Tako Ventures / Dixson Doll (Doll Capital Management) / Ray Bingham, BJ Cassin, other private equity investors / Confidential & Proprietary / 21

**Layout**

Single left-aligned text column starting just below the title and running down the slide, with a two-level bulleted list and a bold lead-in line at the top. The title sits centred horizontally in the upper right area beside the logo, which is at top left. The confidentiality mark and slide number sit in the bottom right corner, with the number at the far right margin. Left margin is about 5.5% of slide width.

**Visuals**

Logo: green Theranos wordmark in a serif-style face with a dark outline and a registered trademark mark (TM) at upper right of the word, at top left. Decorative graphic: a band of blue binary digits (0s and 1s) across the top right, running from about 27% to 95% of slide width and fading from saturated blue at the top-right edge to white toward the left. A second band of blue binary digits lies bottom left, from about 4.5% to 62% of width and 84% to 100% of height, fading to white toward its right end and behind the last bullet lines. No photographs, charts or tables.

**Design**

Background: White #FFFFFF with blue binary-digit bands at top right and bottom left. White background (#FFFFFF) with blue binary-digit header and footer bands in shades of blue (#3F7FCB to #9CC3EA) fading to white. Title in regular sans-serif (Arial/Helvetica style), blue #1F6FB2, about 5.5% of slide height. Body text in Arial/Helvetica-style sans-serif, dark grey #333333, about 2.4% of slide height; the lead-in line and Series A/Series B headings are bold. Level-one bullets are blue #2E6DB4 diamond symbols; level-two bullets are blue #2E6DB4 small squares. Investor names before the colon are underlined by a light shadow effect in the same dark grey. Logo green #3A9A5B. Footer text grey #6D6D6D. No shapes, rules or corner radii; no shadows apart from the text shadow.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- illustration at x 27, y 6, w 68, h 13: Blue binary-digit band at top right fading to white toward the left, behind the title (Blue gradient from #3F7FCB at right edge to white at left, binary digits 0 and 1 in lighter blue, no border)
- illustration at x 4.5, y 84, w 58, h 16: Blue binary-digit band at bottom left fading to white toward the right, behind the last bullets (Blue gradient from #3F7FCB at left to white at right edge, binary digits 0 and 1, no border)
- logo at x 6.5, y 7, w 20, h 7 [#3A9A5B]: Theranos logo wordmark with TM mark (Green serif wordmark with dark outline, TM superscript at upper right)
- title at x 35, y 10, w 30, h 6 [Arial/Helvetica regular sans-serif; font size 5.5% of slide height; #1F6FB2; center aligned]: Existing Investors
- body at x 5.5, y 13.5, w 92, h 72 [Arial/Helvetica regular sans-serif, bold for lead-in and Series headings; font size 2.4% of slide height; #333333; left aligned]: Lead investor profiles: / Series A / Chang, Esoom Taipei: Multi-billion dollar distribution group; leading distributors of high / technology devices in Asia with headquarters in China and in Taiwan. / Continental Properties Company: Fund lead by John Schweitzer and Stephen Feinberg, / director of MD Anderson, leading center in innovative cancer treatment, cutting-edge / research and clinical trials. / Draper Fisher Jurvetson: Draper Fisher Jurvetson is a global network of affiliated venture / funds with over $3 billion in capital commitments and offices in the major technology centers / around the world. / Jupiter Partners: Fund lead by John Bryan, limited partner in numerous venture capital and / private equity funds and leading investor in companies ranging from Amgen to Hewlett / Packard. / Palmieri Trust: Fund lead by Victor Palmieri, business takeover financier; director of / numerous high growth companies including Phillips Petroleum, the Pennsylvania Company, / Arvida Corporation, Outlet Communications, the William Carter Company, Broadcasting / Partners, and Mullin Consulting and a Trustee of The Rockefeller Foundation. / Series B / Donald L Lucas fund: Premier Silicon Valley venture capital veteran (note biography in board / profile document) / ATA Ventures (Early Stage Venture Capital) / Larry Ellison, Tako Ventures / Dixson Doll (Doll Capital Management) / Ray Bingham, BJ Cassin, other private equity investors (Line spacing about 1.2; level-one bullets blue #2E6DB4 diamond symbols; level-two bullets blue #2E6DB4 small squares; investor names underlined by light shadow)
- footer at x 71.5, y 88.5, w 12, h 2.2 [Arial/Helvetica bold sans-serif; font size 1.6% of slide height; #6D6D6D; right aligned]: Confidential & Proprietary
- page number at x 90, y 88, w 3.5, h 3 [Arial/Helvetica regular sans-serif; font size 3% of slide height; #6D6D6D; right aligned]: 21

### Slide 22

**Review notes**

- Review: Several pages have fit and legibility defects: the caption on slide 22 collides with the footer band, slide 23 text overlaps the footer, the chart on slide 13 has overprinted axis labels and unreadable noise, and slide 6 pairs unlabeled drawings with a stock server photo and no explanation.
- Suggested repair: Fix the text colliding with the footer band on slides 22 and 23, enlarge or split the dense management and investor lists on slides 4 and 21, and cut the chart on slide 13 down to a readable message.

**Text**

Technology: Theranos System versus Today's Lab
Theranos™
Normalized response
1 / 0.9 / 0.8 / 0.7 / 0.6 / 0.5 / 0.4 / 0.3 / 0.2 / 0.1 / 0
1 / 10 / 100 / 1000 / 10000 / 100000
Concentration of TxB2 (pg/mL)
Theranos Assay
Conventional Assay
Measured (pg/mL)
Actual (pg/mL, 4x)
5N+1 / 5N-1 / 5A-1 / 5F-2 / 4N+2 / 4A-2 / 4N-3 / 4F-3
Calculated Concentration pg/mL (log scale)
Spiked Concentration pg/mL (log scale)
All data / Subject 4 / Subject 5 / Linear (All data)
Signal (RLU)
Concentration of TxB2 (pg/mL)
Sample 4 / Sample 5 / Calibration
Luminometer correlation
Upper end of linear range
y = 0.9334x + 0.3992 / R² = 0.9915 / R = 0.995
Projected signal / modulation of / Theranos Chip-/ based assay in / 5 uL volume
Log Theranos Response (Counts/sec)
Log MD response (counts/sec)
Luminometer correlation / Linear (Luminometer correlation)
On chip Chemiluminescence enables greater sensitivity than the clinical / lab
Confidential & Proprietary
22

**Layout**

Full-bleed white slide with a blue binary-code banner across the top right and bottom left. Logo sits top left, the title runs across the top below the logo, and a five-chart arrangement fills the middle: a top row of two charts and a bottom row of three charts in a grid with white gaps. The takeaway line sits bottom left over the lower banner, with the confidentiality mark and slide number bottom right.

**Visuals**

Five charts. (1) Line and scatter chart, Normalized response (0 to 1, linear) versus Concentration of TxB2 (pg/mL) (1 to 100000, log scale); Theranos Assay series is blue diamond markers with a blue fitted curve, Conventional Assay series is red square markers with an orange fitted curve; no values printed, about 1.0 at 1 pg/mL falling to about 0.05 at 100000 pg/mL; legend in a box inside the plot at lower left; points at about 1000 pg/mL cross near 0.6; boxed by a thin grey frame. (2) Log-log scatter, Measured (pg/mL) axis 0.1 to 100000 versus Actual (pg/mL, 4x) axis 0.1 to 100000; eight series of small coloured markers (5N+1 black diamond, 5N-1 magenta square, 5A-1 yellow triangle, 5F-2 cyan x, 4N+2 purple x, 4A-2 dark red circle, 4N-3 teal plus, 4F-3 blue plus) clustered on a thin black diagonal line; legend box at right. (3) Scatter, Calculated Concentration pg/mL (log scale) 1.0 to 5.0 versus Spiked Concentration pg/mL (log scale) 1.0 to 5.0; All data as small black dots, Subject 4 as magenta open squares, Subject 5 as dark magenta open triangles, a black linear trend line; legend box at lower right of plot; framed by a thin purple-grey box. (4) Scatter with curve, Signal (RLU) 0 to 50000 versus Concentration of TxB2 (pg/mL) 10 to 100000 (log scale); Sample 4 dark teal squares, Sample 5 orange-red diamonds, dark grey Calibration curve that is flat near 40000 at low concentration, falls steeply between 100 and 3000, then levels near 5000 at 100000; legend box at upper right; framed by a thin purple-grey box. (5) Scatter with linear fit, Log Theranos Response (Counts/sec) 2.0E+00 to 7.0E+00 versus Log MD response (counts/sec) 2.0E+00 to 7.0E+00; navy diamond markers rising from about 2.5 to 6.5 with a dark navy linear fit line; horizontal red line at 6.5E+00 labelled Upper end of linear range; text y = 0.9334x + 0.3992, R² = 0.9915, R = 0.995; red vertical double-headed arrow at right with the annotation Projected signal modulation of Theranos Chip-based assay in 5 uL volume; legend box at bottom with Luminometer correlation and Linear (Luminometer correlation). Also a Theranos logo, a blue binary-code banner (repeated 0 and 1 digits) at the top right and bottom left.

**Design**

Background: White #FFFFFF with blue binary-code banners top right and bottom left. White background. Title 'Technology:' in blue #1F6FA8 and 'Theranos System versus Today's Lab' in coral orange #F08A62 with an orange underline. Body text in dark grey #333333. Typeface is Arial-like sans-serif, title regular weight, about 4.2 percent of slide height; subtitle about 3.6 percent. Chart text is small Arial sans-serif in dark grey. Charts have thin grey or purple-grey frames, no shadows, no rounded corners. Logo in green #2E9E6A. Binary banner in blue #2F6FB5 fading to white.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 27, y 5.8, w 68.5, h 13.6 [#2F6FB5]: Blue binary-code banner, top right, fading to white on its left edge (Gradient fade from solid blue at right to white at left; sits behind the title.)
- logo at x 6.8, y 7.8, w 19.8, h 5.2 [#2E9E6A]: Theranos logo with TM mark (Green serif wordmark with a caduceus-like figure at the T; TM superscript at upper right.)
- title at x 13, y 14.3, w 74, h 4.5 [Arial sans-serif, regular weight, no caps; font size 4.2% of slide height; #1F6FA8 and #F08A62; left aligned]: Technology: Theranos System versus Today's Lab ('Technology:' in blue #1F6FA8; remainder in orange #F08A62 with a thin orange underline spanning the words.)
- chart at x 7.9, y 21.9, w 37.2, h 27 [#FFFFFF]: Normalized response versus Concentration of TxB2 (pg/mL) line and scatter chart with Theranos Assay and Conventional Assay series (Thin grey frame; legend box inside plot at lower left with blue diamond Theranos Assay and red square Conventional Assay; blue and orange curves.)
- chart at x 48.8, y 23.7, w 38.3, h 24.9 [#FFFFFF]: Measured (pg/mL) versus Actual (pg/mL, 4x) log-log scatter with eight series and diagonal line (No frame; legend box at right with small coloured markers; thin black diagonal line.)
- chart at x 4.9, y 52.4, w 31.2, h 29.3 [#FFFFFF]: Calculated Concentration pg/mL (log scale) versus Spiked Concentration pg/mL (log scale) scatter with All data, Subject 4, Subject 5 and linear fit (Thin purple-grey frame; legend box at lower right; black trend line.)
- chart at x 37.4, y 52.4, w 30.5, h 29.4 [#FFFFFF]: Signal (RLU) versus Concentration of TxB2 (pg/mL) scatter with Sample 4, Sample 5 and Calibration curve (Thin purple-grey frame; legend box at upper right; teal squares, orange-red diamonds, dark grey curve.)
- chart_caption at x 76.4, y 50.5, w 8.5, h 1.1 [Arial sans-serif, regular weight; font size 1.3% of slide height; #333333; center aligned]: Luminometer correlation
- chart at x 67.5, y 50.5, w 28.1, h 33 [#2B2B5A]: Log Theranos Response (Counts/sec) versus Log MD response (counts/sec) scatter with linear fit, red upper-limit line, equation and red annotation arrow (Navy diamonds, dark navy fit line, red horizontal line at 6.5E+00 and red double arrow at right; legend box at bottom.)
- shape at x 4.5, y 82.3, w 58.3, h 12 [#2F6FB5]: Blue binary-code banner, bottom left, fading to white on the right (Gradient from blue at left to white at right; sits behind the takeaway line.)
- body at x 9.3, y 85.2, w 72.3, h 6.8 [Arial sans-serif, regular weight, no caps; font size 3.6% of slide height; #333333 with 'Chemiluminescence' in #F08A62; left aligned]: On chip Chemiluminescence enables greater sensitivity than the clinical / lab (Two lines; 'Chemiluminescence' underlined in orange #F08A62; line spacing about 1.0; second line 'lab' starts at left margin.)
- footer at x 71.7, y 88.9, w 14.1, h 1.7 [Arial sans-serif, regular weight; font size 1.7% of slide height; #7F7F7F; right aligned]: Confidential & Proprietary
- page number at x 90.2, y 89.1, w 2.2, h 2.2 [Arial sans-serif, regular weight; font size 2.2% of slide height; #7F7F7F; right aligned]: 22

### Slide 23

**Review notes**

- Review: Several pages have fit and legibility defects: the caption on slide 22 collides with the footer band, slide 23 text overlaps the footer, the chart on slide 13 has overprinted axis labels and unreadable noise, and slide 6 pairs unlabeled drawings with a stock server photo and no explanation.
- Suggested repair: Fix the text colliding with the footer band on slides 22 and 23, enlarge or split the dense management and investor lists on slides 4 and 21, and cut the chart on slide 13 down to a readable message.

**Text**

Theranos
Computation of results
12000
10000
8000
6000
4000
2000
0
Signal
Measured signal (sent to Theranos server)
Dose-response relationship (Factory calibration)
Derived concentration
1
10
100
1000
10000
100000
Progesterone concentration in diluted sample (pg/ml)
Concentration in sample = Signal >> Derived conc. * Dilution factor (fixed)
Computation performed at Theranos server
Chemistry is calibrated through Theranos server by comparing results on cartridge to known results for calibration wells in database so as to preempt use of environmentally deteriorated cartridges
Confidential & Proprietary
23

**Layout**

Single-column slide with the logo at top left and the title directly beneath it, left-aligned at about 13% of the slide width. A bordered chart panel fills the middle, with three left-aligned text lines below it and a three-line body paragraph at the bottom left. The footer 'Confidential & Proprietary' and page number 23 sit at the bottom right, on the same baseline. Binary-code banners run across the top right and bottom left corners.

**Visuals**

Line chart with no chart title. Y axis: linear, 'Signal' (no units), range 0 to 12000, major ticks every 2000. X axis: logarithmic, 'Progesterone concentration in diluted sample (pg/ml)', range 1 to 100000, ticks at 1, 10, 100, 1000, 10000, 100000. One series, a dark grey (#333333) curve about 1.5 px wide with no markers: about 10900 at x=1, about 10600 at x=10, about 9600 near x=50, then falling steeply through about 6000 near x=250 and about 2000 near x=2000, flattening to about 900 from x=50000 to x=100000. No printed data values; all values are estimates. No legend. Annotations: a red horizontal arrow at signal about 9300 running from the y-axis (x=1) to the curve (x=about 60), with a red vertical arrow dropping from the curve at x=about 65 to the x-axis at 0; the red arrowheads mark the measured point on the curve and the derived concentration on the axis. Dark grey thin arrows point from the labels 'Measured signal (sent to Theranos server)' to the red start point, from 'Dose-response relationship (Factory calibration)' to the curve at about x=200, and from 'Derived concentration' to the red arrow tip on the axis. Chart panel is boxed by a thin grey (#999999) 1 px border with a white fill.

**Design**

Background: Solid white #FFFFFF with blue binary-code gradient banners at top right and bottom left. White background with blue and green brand accents. Title in bold Arial-like sans-serif, blue #0F6A9E, about 5% of slide height. Body text in regular Arial-like sans-serif, dark grey #333333, about 3.2% of slide height. Chart labels in regular sans-serif #333333, about 2.6% of slide height; axis title bold. Footer in bold sans-serif grey #666666, about 1.6% of slide height. Page number in regular sans-serif grey #666666. Logo in green #3A9A5A with a serif wordmark and a small trademark mark. Chart border thin grey #999999, square corners, no shadow. Red annotation lines #E01E1E, about 1.5 px. Binary-code banners are blue (#2A6FC0 fading to white) with white binary digits, no corner radii, no shadows.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- illustration at x 26.5, y 5.8, w 68.5, h 12.6: Binary-code banner, blue gradient fading to white, top right (Sits behind the title and logo area; fades to transparent toward the left and bottom.)
- illustration at x 4.5, y 82.2, w 58.5, h 12.6: Binary-code banner, blue gradient fading to white, bottom left (Sits behind the bottom body text; text overlaps its right part.)
- logo at x 6.75, y 7.8, w 19.75, h 5.2 [#3A9A5A]: Theranos logo with TM mark (Green serif wordmark with a caduceus-like stylised T and a small trademark symbol at top right.)
- title at x 13.1, y 15.2, w 41.4, h 4.2 [Arial, bold; font size 5% of slide height; #0F6A9E; left aligned]: Computation of results
- shape at x 14.25, y 20.5, w 72.65, h 51.8 [#FFFFFF]: Chart panel border, white fill (Thin grey #999999 1 px square border.)
- chart at x 14.25, y 20.5, w 72.65, h 51.8 [#333333]: Line chart of signal versus progesterone concentration, with red and dark grey annotation arrows as described in visuals (Log x-axis from 1 to 100000 and linear y-axis from 0 to 12000; single curve; red arrows overlay the plot.)
- body at x 20, y 23.5, w 5.5, h 30.5 [Arial, regular; font size 2.6% of slide height; #333333; right aligned]: 12000 / 10000 / 8000 / 6000 / 4000 / 2000 / 0 (Y-axis tick labels, stacked vertically at equal spacing.)
- body at x 16.5, y 37.9, w 2, h 7.8 [Arial, bold; font size 2.6% of slide height; #333333; center aligned]: Signal (Y-axis title rotated 90 degrees counterclockwise.)
- body at x 26.25, y 61.5, w 59.25, h 2.7 [Arial, regular; font size 2.6% of slide height; #333333; left aligned]: 1 / 10 / 100 / 1000 / 10000 / 100000 (X-axis tick labels spaced along the bottom axis, each centred under its tick.)
- body at x 29.4, y 66.7, w 50, h 2.6 [Arial, bold; font size 2.6% of slide height; #333333; center aligned]: Progesterone concentration in diluted sample (pg/ml)
- body at x 28.25, y 34.3, w 17.75, h 10.4 [Arial, regular; font size 2.8% of slide height; #333333; center aligned]: Measured signal (sent to Theranos server) (Three lines: 'Measured signal' / '(sent to Theranos' / 'server)'. Dark grey arrow points to the red start point on the curve.)
- body at x 65.75, y 28.5, w 11.75, h 17.5 [Arial, regular; font size 2.8% of slide height; #333333; center aligned]: Dose-response relationship (Factory calibration) (Lines: 'Dose-' / 'response' / 'relationship' / '(Factory' / 'calibration)'. Thin dark grey arrow points to the curve at about x=200.)
- body at x 31.4, y 50.2, w 13.75, h 6.5 [Arial, regular; font size 2.8% of slide height; #333333; center aligned]: Derived concentration (Two lines: 'Derived' / 'concentration'. Small dark arrow points to the red arrow tip on the x-axis.)
- line at x 26.5, y 31.5, w 20, h 30 [#E01E1E]: Red measured-signal arrow and red derived-concentration arrow (Horizontal red line at about signal 9300 with arrowhead at the curve, and vertical red line dropping to the x-axis with arrowhead at about x=65; line width about 1.5 px.)
- body at x 12.3, y 72.5, w 74.1, h 3.2 [Arial, regular; font size 3.2% of slide height; #333333; left aligned]: Concentration in sample = Signal >> Derived conc. * Dilution factor (fixed)
- body at x 12.3, y 78, w 43.5, h 3.2 [Arial, regular; font size 3.2% of slide height; #333333; left aligned]: Computation performed at Theranos server
- body at x 13.85, y 82.5, w 70, h 10.4 [Arial, regular; font size 3.2% of slide height; #333333; left aligned]: Chemistry is calibrated through Theranos server by comparing results / on cartridge to known results for calibration wells in database so as to / preempt use of environmentally deteriorated cartridges (Three lines with the first indented slightly further than the others; line spacing about 3.7% of slide height.)
- footer at x 71.65, y 88.8, w 14.1, h 1.6 [Arial, bold; font size 1.6% of slide height; #666666; right aligned]: Confidential & Proprietary
- page number at x 90.15, y 88.8, w 2.1, h 2.3 [Arial, regular; font size 3.2% of slide height; #666666; right aligned]: 23
